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ABSTRACT 
An Inhalation Model of Acute Q Fever in Guinea Pigs. (December 2006) 
Kasi Elizabeth Russell-Lodrigue, D.V.M., Louisiana State University 
Co-Chairs of Advisory Committee:   Dr. James E. Samuel 
            Dr. Andres de la Concha-Bermejillo 
 
 
Coxiella burnetii is an intracellular pathogen that can cause both acute and 
chronic disease (Q fever) in humans and infects many animals with varying clinical 
illness and persistence. A guinea pig aerosol-challenge model of acute Q fever was 
developed using infection with C. burnetii across a 5-log range of challenge doses. 
Clinical signs included fever, weight loss, respiratory difficulty, and death, with degree 
and duration of response corresponding to dose of organism delivered. Histopathologic 
evaluation revealed coalescing panleukocytic bronchointerstitial pneumonia 7 days after 
a high-dose challenge, resolving to multifocal lymphohistiocytic interstitial pneumonia 
by 28 days. Clinical and pathologic changes noted in these guinea pigs were comparable 
to those seen in human acute Q fever, making this an accurate and valuable animal 
model. This model was used to compare the relative virulence of eight isolates from four 
different genotypic groups: I (RSA493, RSA334, and RSA270), IV (Q177 and Q173), V 
(Q212 and Q217), and VI (5J108-111). Guinea pigs infected with group I acute-disease-
associated isolates had severe respiratory disease, while no to moderate clinical illness 
was observed in animals given group IV or V chronic-disease-associated isolates. 5J108-
111 appeared avirulent. These data suggest that C. burnetii isolates have a range of 
disease potentials and support a distinction in strain virulence between established 
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genotypic groups, though isolates within the same genomic group cause similar 
pathologic responses. Heterologous protection was confirmed by cross vaccination and 
challenge with RSA493 and Q217. A marked non-specific suppression of 
lymphoproliferation was noted at 14 and 28 days post infection with RSA493; similar 
suppression was seen after infection with Q173 and Q212 but not 5J108-111. Pro-
inflammatory cytokines IFN-γ and TNF-α were produced during early C. burnetii 
infection, at which time anti-inflammatory cytokines TGF-β and IL-10 were repressed. 
A vaccine made from phase I C. burnetii was found to be completely protective against 
lethal infection in the guinea pig model, while vaccination with killed phase II organisms 
conferred only partial protection, preventing death and reducing but not precluding fever 
and respiratory illness. Protective vaccination significantly stimulated cell-mediated 
immunity and elicited increases in IFN-γ, TNF-α, and IL-12p40 mRNA levels. 
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I. INTRODUCTION  
  
Q (“Query”) fever is a zoonotic disease of worldwide significance caused by the 
obligate intracellular bacterium Coxiella burnetii. The first published account of the 
disease was in Australia in 1937, and it was originally suspected to be caused by a virus 
(34). The following year, researchers in the United States reported the isolation of a 
rickettsial agent from ticks that they called “Nine Mile agent,” now identified as C. 
burnetii (30, 35). The organism commonly infects sheep, goats, and cattle, and human 
infection arises primarily from inhalation of contaminated materials from these animals 
(6). C. burnetii can withstand desiccation and remain infectious in contaminated soils for 
years (163) and has a high degree of resistance to physical and chemical agents (8, 119, 
143). Due to the highly infectious nature of C. burnetii and its hardiness in adverse 
environmental conditions, the organism has been included in the list of weapons of mass 
destruction likely to be used in bioterrorism and biological warfare and is considered a 
Category B agent by the Centers for Disease Control and Prevention (39, 85). The 
weaponization and mass-production of C. burnetii has already been achieved (133, 151), 
accentuating the need for a safe, effective vaccine to protect populations at risk 
subsequent to a deliberate or natural outbreak. 
 
 
 
                                                 
  This dissertation follows the style of Infection and Immunity. 
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THE ORGANISM 
C. burnetii is the only member of the genus Coxiella. Phylogenetic investigations 
indicate that C. burnetii is most closely related to Wolbachia, Francisella, and 
Legionella, as evidenced by 16S RNA sequencing (173) and multiple individual gene 
sequences (114). The genome of C. burnetii, Nine Mile isolate, has recently been 
sequenced by the Institute for Genomic Research. The chromosome is 1.99 Mb and 
circular in nature with ~2100 open reading frames (ORF). Additional genetic 
information is present in the form of circular plasmid DNA that ranges in size among 
isolates from 32 to 56 kb; plasmidless isolates contain plasmid-related sequences 
integrated into their chromosomes (145).  
C. burnetii isolates have been obtained worldwide from natural acute and chronic 
Q fever infections in humans and other animals. Studies comparing the plasmid profiles 
(140), chromosomal RFLPs (55), and LPS banding patterns (47) established a distinction 
between acute isolates and chronic isolates, and six major strains were described based 
on these biochemical markers (91). Genomic groups I-III have a QpH1 plasmid and 
were historically associated with isolates found in animals and acute human Q fever; 
groups IV and V, containing a QpRS plasmid or no plasmid, respectively, were 
associated with Q fever endocarditis or disease in livestock; and group VI isolates with 
the QpDG plasmid from feral rodents in Utah had undefined pathogenicity (107). A 
recent study using a comprehensive microarray- based whole genome comparison 
confirmed the relatedness of RFLP-grouped isolates and added two more genomic 
groups, VII and VIII (12). Unique sequence differences between genomic groups could 
  
3
influence the clinical expression of Q fever (140).  However, predisposing host factors 
may be as important as strain variety in the development of acute or chronic illness (82, 
126, 188). 
C. burnetii has evolved the ability to survive in harsh environments that are lethal 
to most bacterial species. It has developed specialized forms for propagation, enduring 
intracellular stresses, and surviving and persisting in an extracellular environment. These 
forms have been studied and described since the organism’s discovery in the 1930’s 
(30). Numerous models of the developmental cycle of C. burnetii have been proposed 
over the years, many describing it as similar to the life cycle model of Chlamydia. The 
most recent new developmental life cycle model (52, 139) was based on evidence of 
differential protein expression between separable forms designated large cell variants 
(LCV) and small cell variants (SCV). LCV and SCV may represent a novel adaptation 
for survival in both the phagolysosome and the extracellular environment (146). Both 
SCVs and LCVs have a Gram-negative cell wall typical of eubacteria with two layers 
separated by a periplasmic space. In SCVs, the periplasmic space is densely filled with 
proteins and peptidoglycan, which may enhance the resistance of this variant to 
environmental conditions. LCVs and SCVs, separated by a density gradient system, have 
both been demonstrated to be infectious (175).  
Antigenic variations seen in C. burnetii are similar to those recognized in 
enterobacteria like Escherichia coli. Phase variation is the only well characterized 
phenotypic difference that relates to virulence in C. burnetii(160); phase variation and 
virulence are primarily related to mutational variation in the lipopolysaccharide (LPS) 
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(47-49). Virulent phase I C. burnetii possesses a smooth LPS layer; deletions of the O-
side chain and certain sugars result in the rough LPS of avirulent phase II(142). Recent 
microarray-based whole genome comparison of Nine Mile phase I to variants with 
attenuated virulence showed that the only difference between the virulent and avirulent 
forms lie in the deletion of LPS biosynthesis genes(12), as has been previously 
suggested(59). Virulence is clearly defined in phase I, the highly infectious phase 
isolated in natural infections. Strains convert to phase II after multiple serial passages in 
cell or embryonated egg cultures and require a large number of organisms for infection 
to occur (40, 125). One study suggests that this relative avirulence of phase II organisms 
may be due to preferential complement receptor uptake targeting phase II for killing by 
macrophages/monocytes (111). The smooth LPS expressed by phase I cells may play an 
important role in protecting the microorganism from the host’s microbicidal activities 
(178), thus allowing the infection to progress. Genetically isolated groups may also 
differ in phase I LPS (47). LPS differences are known to be responsible for many of the 
virulence effects of other Gram-negative bacteria; whether a variation in the phase I LPS 
of C. burnetii isolates is linked to virulence is not yet known. C. burnetii LPS is less 
pyrogenic than that of most Gram-negative bacteria (72) and may therefore only have a 
minor role in the fever response to infection. The combination of a variety of factors 
expressed by phase I bacteria likely govern the ability of C. burnetii to infect cells and 
maintain continuous growth within the phagolysosome. The recent study by Beare, et al, 
comparing all open reading frames (ORF) of Nine Mile phase I to several other isolates 
showed that a majority of the ORFs deleted from Nine Mile in the other isolates were 
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either hypothetical or nonfunctional, but some were associated with assorted cellular 
functions(12). 
C. burnetii invades the host cell by a microfilament-dependent, parasite directed, 
endocytic process (9). Once inside the cell, the organism takes up residence in a 
parasitophorous vacuole with characteristics of a secondary lysosome and may be the 
only intracellular bacteria to replicate in this acidified space. C. burnetii enter and 
replicate in a variety of epithelial, fibroblast, and macrophage-like cell lines (10). In 
vivo, the initial target in aerosol infection is the alveolar macrophage, after which the 
organism is disseminated to replicate in a multitude of tissues. Despite a relatively slow 
replication rate (12-48 hour doubling time), the organism reaches high numbers within 
the parasitophorous vacuole and survives many toxic host factors normally considered to 
be bactericidal, such as acid hydrolase, oxygen and nitrogen radicals, and defensins (10).  
 The nature of the intracellular killing mechanisms that C. burnetii is exposed to 
and mechanisms to evade or overcome these host factors are not well understood. Two 
early studies demonstrated that interferon gamma (IFN-γ) could induce both guinea pig 
monocytes and L929 fibroblasts to inhibit the replication of C. burnetii, though growth 
was not hindered by type I interferons (56, 167). Another study evaluated the potential 
killing mechanisms of IFN-γ-stimulated monocytes to control C. burnetii replication 
using the THP-1 monocyte cell line(32) where THP-1 cells infected  with C. burnetii for 
24 hours and treated with IFN-γ expressed a high level of TNF-α; this cytokine appeared 
to drive infected cells into an apoptotic death. Studies by Howe, et al. (62), and Brennan, 
et al. (16),  demonstrate that nitric oxide in L929 fibroblasts and nitric oxide plus oxygen 
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radicals, respectively, participate in control of C. burnetii replication by IFN-γ-
stimulated cells. Zamboni (190) and Brennan (16) obtained similar results in mouse 
peritoneal macrophages and also showed that the effects of IFN-γ are not exclusively 
reliant on nitric oxide production since IFN-γ also controlled the infection in 
macrophages obtained from inducible nitric oxide synthase (iNOS) knockout mice. This 
may be due, in part, to the action of indoleamine 2,3-dioxygenase(136). 
 
THE DISEASE 
Q fever is considered primarily an occupational hazard in people who frequently 
have contact with domestic livestock such as sheep, goats, and cattle (107), though the 
disease may be contracted from pets including dogs and cats (20, 101, 124). C. burnetii 
has also been documented in several other mammals, birds(156, 165), reptiles(84, 157, 
186), and arthropods(14, 30, 153). C. burnetii has a high affinity for the placenta and is 
routinely shed in birthing fluids and tissues, milk, urine, and feces. Humans are most 
often infected through inhalation of the organism in fine-particle aerosols, with as few as 
10 organisms leading to disease (13). Transmission may also occur through ingestion of 
the organism from contaminated, unpasteurized, dairy products (63, 86). Due to the 
bacteria’s ability to persist in the environment, even inhalation of contaminated dust 
particles can lead to infection(31, 187). Individuals at the highest risk of contracting Q 
fever include farmers, abattoir workers, veterinarians, and laboratory personnel 
performing C. burnetii cultures or working with infected animals. In the past two 
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decades, several outbreaks of infection in medical research facilities working with 
pregnant ewes have been described(113, 147, 152).  
Q fever can manifest as either an acute or chronic illness. Humans developing 
acute disease often present with a flu-like illness with hallmark cyclic fever (104-105°F) 
and severe periorbital headache(129); other symptoms may include malaise, myalgia, 
fatigue, non-productive cough, nausea/vomiting, diarrhea, and weight loss. Most cases of 
Q fever are not recognized or diagnosed since acute illness often falls within the group 
of “fever of unknown origin” syndromes (37), and as many as 50% of exposed persons 
may develop an antibody response without showing signs of clinical illness (110). 
Common complications include pneumonia and hepatitis, but acute disease is almost 
always self-limiting. Q fever pneumonia is characterized by gross consolidation of the 
lungs and an interstitial pneumonia with bronchial and alveolar exudates and 
inflammatory infiltrates mainly consisting of lymphocytes and macrophages (98, 100, 
118). Liver biopsy samples from human acute Q fever cases primarily exhibit 
granulomatous hepatitis with characteristic “doughnut” granulomas, a central vacuole 
surrounded by a fibrin ring. Though this type of granuloma is often found in Q fever 
cases, it is not specific to this disease, also occurring in cases of infectious 
mononucleosis and Hodgkin’s disease, among others (99). Portal triaditis, Kupffer cell 
hyperplasia, and moderate fatty change have also been described in association with 
acute Q fever hepatitis (107).  Acute illness is most successfully treated with 
tetracyclines, though various other antibiotics have also shown some efficacy (127).  
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Chronic infection is contracted less frequently than acute disease but bears a 
poorer prognosis. Chronic Q fever most often presents as endocarditis and/or hepatitis 
but has also has been diagnosed in cases of osteomyelitis (117, 130) Recognition of 
these infections is increasing worldwide, though Q fever is still considered a rare cause 
of endocarditis overall. Endocarditis caused by C. burnetii has an atypical presentation: 
bacterial vegetation with bacteria embedded in necrotic inflammatory debris and fibrin 
does not occur (as would be expected with the typical valvular endocarditis), and blood 
cultures are negative (82). It has been suggested that acute infection with C. burnetii is a 
predisposing factor for long-term vascular inflammation, and latent vascular infection 
may occur similar to that noted for Chlamydia pneumoniae and other infectious agents 
(80, 138). 
The doughnut granulomas typical of acute Q fever are not found in chronic Q 
fever hepatitis, which primarily presents as lymphocytic infiltration along portal tracts, 
nonspecific granulomas, and focal necrosis (37, 174). A relationship has also been 
discovered between Q fever and a chronic fatigue-like syndrome (93, 96, 122, 177).  
Chronic infections appear to be associated with a suppression of the cell-mediated 
immune system (126), and patients with HIV are known to be at particular risk (131). In 
these immunocompromised individuals, antigen-specific lymphoproliferation and IFN-γ 
synthesis are down regulated (65, 77, 78), and tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) are up regulated in patients with endocarditis (26). The antigen-
specific lymphocyte unresponsiveness is mediated in part by adherent suppressor cells 
via prostaglandin E2 (PGE2) production (77). Chronic Q fever has been linked to 
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overproduction of interleukin-10 (IL-10) and deficient killing of C. burnetii by 
monocytes(42). Elevated IL-10 expression is associated with a poor disease outcome and 
has been specifically linked with the incidence of relapses (25). Unlike acute infections, 
chronic infections do not respond well to antibiotic therapy (30, 35). Combination 
treatment regimens such as doxycycline and chloroquine taken for extended periods are 
most successful (105, 106).  
 
ANIMAL MODELS 
The majority of C. burnetii studies utilize mice or guinea pigs as experimental 
models, though sheep (18) and non-human primates (21, 46) have also been used. Mice 
are most commonly used due to the many genetic and immunologic tools available for 
this species. Acute infection in various mouse strains is defined as lethality (144) or 
splenomegaly (38), whereas the development of fever is used as the indicator of disease 
in guinea pigs (51). Mice are essentially a clearance model, relying on a mouse’s ability 
to control infection after uptake of the organism. Guinea pigs can be used as a model of 
protection against clinical disease and are thus more relevant for testing vaccines for 
human use. Mice have generally been inoculated intraperitoneally (IP), and as with 
many diseases, the strain of mouse is significant and determines the course of infection 
with C. burnetii, with responses ranging from very low morbidity in less susceptible 
mice (e.g., C57BL/6J mice) to severe illness and death in the most susceptible strains 
(e.g., A/J mice) (144). Even susceptible mice must be inoculated with large quantities of 
C. burnetii (>108 organisms) to develop overt clinical signs of disease. On the other 
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hand, guinea pigs inoculated IP with as few as ten virulent organisms develop fever 
within five days (116), and bacteria can be isolated from a variety of tissues, including 
the spleen, for several months post-infection. A majority of the research done with 
guinea pigs and C.  burnetii has involved infection via IP inoculation; however, the 
clinical signs developed in this model do not adequately mirror the respiratory 
component seen in natural human infections. Both infection route and inoculum size 
have been shown to determine the clinical manifestations of disease (83), with a higher 
incidence of pneumonia, a common complication of Q fever in humans (68), seen in 
guinea pigs infected via aerosol and more severe signs of hepatitis, which is associated 
with ingestion of C. burnetii contaminated dairy products in humans(164), in IP-infected 
animals. A comparison of the relative virulence of isolates from acute genomic group I 
Nine Mile phase I and chronic genomic group IV Priscilla phase I infections showed that 
>104 inclusion forming units (IFU) of chronic isolate were required for demonstrable 
fever in guinea pigs versus the 10 IFU needed with acute isolates (116). Guinea pigs 
have also been used to study the endocarditis aspect of C. burnetii infection by 
inoculation with C. burnetii Nine Mile phase I after electrocoagulation of native aortic 
valves (82).  
Previous studies exposing guinea pigs to C. burnetii via aerosol have used only 
single, moderate to high doses of the organism for disease induction. The methods used 
to determine the amount of organism delivered in a majority of these studies did not 
quantify C. burnetii, instead relying on indirect assessments of bacterial burden, such as 
egg and mouse median infectious doses (71, 73). Other common assays used to 
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determine the amount of organism delivered by IP and aerosol infection include direct 
particle count, inclusion forming units (IFU), and plaque forming units (PFU). Guinea 
pigs infected with C. burnetii intranasally develop a higher incidence of pneumonia; 
those infected IP develop more severe signs of hepatitis (83), a significant finding since 
the route of infection is also known to determine the clinical manifestations of acute Q 
fever in humans (102). It is unknown at this time what effect low doses of organism 
delivered by aerosol would have on the development of respiratory and/or hepatic 
changes in the guinea pig. This information is of vital importance in the development of 
an adequate inhalation model of Q fever for multiple reasons, including inference of 
human response to similar doses and establishment of baseline data for vaccine and other 
studies. 
 
VACCINE STUDIES 
A lot of the work with animal models of C. burnetii infection has been to further 
the development of a safe, effective vaccine for use in humans. Formalin-killed bacteria 
have been used historically to produce a protective immune response and are known to 
be highly immunogenic and protective in both humans and animals (1, 179).  
Unfortunately, this vaccine can lead to the development of severe necrotic lesions at the 
site of injection in a small fraction of patients, usually due to prior exposure to C. 
burnetii. Organic solvent extraction partially eliminated the primary antigenic 
components that caused the DTH-type necrotic reactions (180), and this material has 
been used in a range of vaccine studies showing good efficacy (183). A killed, whole-
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cell vaccine has been developed and is used in Australia (Qvax; CSL Ltd., Melbourne, 
Australia) in conjunction with a skin test prior to vaccination to avoid potential adverse 
reactions (95). These vaccines are currently not available for use in most countries, 
including the United States. The immune response seen post-vaccination in humans has 
been evaluated through cell mediated immunity, known to be a factor in resistance to C. 
burnetii infection(107), and antibody response(7, 185). The killed whole cell vaccine 
(WCV) has been shown to elicit humoral antibodies and protect against disease in man 
and guinea pigs (112, 150). IgG1, IgG2 and IgA1 subclasses were found to predominate 
both in natural infection and post vaccination with a soluble phase I C. burnetii extract 
(22). Lymphoproliferation is noted in humans after vaccination with WCV (65, 66), and 
T cell immunity is known to be effective in the control of natural Q fever infection 
(107). Studies in the early 60’s showed that a killed whole cell vaccine made from phase 
I and phase II organisms have differential protectivity against infection with phase I 
bacteria, with phase I vaccines being 100-300 times more effective (120). In vitro studies 
with peritoneal macrophages from phase I and phase II immunized guinea pigs 
subsequently infected with phase I or II organisms showed that only phase I organisms 
were destroyed by macrophages from phase I immunized animals (76). Other mouse 
protective immunity studies may indicate a Th1 requirement for protection, based on the 
cytokines detected (166, 170).  
Subunit vaccine development efforts for C. burnetii have been moderate to date 
(181, 182), but are supported by limited prior studies. BALB/c/Han mice immunized 
twice with various amounts of a partially purified 29 kDa membrane antigen in the 
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context of complete Freund’s adjuvant and then challenged with 105 EID50 (50% egg 
infectious dose) had splenic bacterial burdens decreased by ~3 logs at the highest 
immunization doses (88). A partially purified 67 kDa antigen in another study used in 
both guinea pigs and BALB/c mice was determined to be fully protective at two doses of 
100μg in incomplete Freund’s adjuvant (191).  
 The guinea pig model of aerosol infection with C. burnetii provides an excellent 
resource for a second level of evaluation of potential vaccine candidates after initial 
testing in the mouse model and prior to proposal for human studies. Once the guinea pig 
aerosol challenge model is available and adequately characterized, it can be used to 
evaluate multiple alternate vaccine strategies including recombinant antigens, T-cell 
epitopes, and DNA vaccination. This model can also be integrated into diverse projects 
and will be supportive for testing pathogenesis of disease, diagnostic techniques, and 
treatment/prevention strategies.  
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II. CLINICAL AND PATHOLOGIC CHANGES IN A GUINEA PIG AEROSOL-
CHALLENGE MODEL OF ACUTE Q FEVER∗ 
 
INTRODUCTION 
 Q fever is a disease of worldwide importance to both humans and other animals 
caused by the obligate intracellular bacterium Coxiella burnetii. Sheep, goats, and cattle 
are the primary reservoirs of the organism and can shed it in milk, urine, feces, and birth 
products  (6). Thus, occupational exposure of persons in contact with these animals, such 
as abattoir workers, farmers, and veterinarians, is associated with a higher risk of 
contracting Q fever. C. burnetii has also been found in numerous other mammals, birds 
(156, 165), reptiles (84, 157, 186), and arthropods (14, 30, 153). Humans are primarily 
infected through inhalation, and as few as 10 organisms are known to cause disease (13). 
Ingestion of contaminated dairy products (63, 86, 164) or bites from infected ticks (30, 
35, 134)may also lead to infection. 
C. burnetii has a high degree of resistance to physical and chemical agents (119, 
143) and can withstand desiccation and remain infectious in contaminated soils for years 
(163). Due to the highly infectious nature of C. burnetii and its hardiness in adverse 
environmental conditions, the organism is considered a Category B agent by the Centers 
for Disease Control and Prevention and has been included in the list of weapons of mass 
destruction likely to be used in bioterrorism and biological warfare (39, 85). 
                                                 
∗ Reprinted with permission from K.E. Russell-Lodrigue, G.Q. Zhang, D.N. McMurray, and J.E. Samuel. 
2006. Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. Infect 
Immun 74(11):6085-6091. 
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Weaponization and mass-production of this organism has already been accomplished 
(133, 151), reinforcing the need for a safe, efficacious vaccine that could be used to 
protect populations at risk following a deliberate or natural outbreak. 
 Human Q fever can present either as acute or chronic infection. Acute Q fever 
generally presents as a flu-like illness with severe periorbital headache, high fever, 
malaise, myalgia, rare non-productive cough, and weight loss (98, 107). This illness can 
progress to Q fever pneumonia, characterized by gross lung consolidation and an 
interstitial pneumonia with bronchial and alveolar exudates and inflammatory infiltrates 
primarily consisting of lymphocytes and macrophages (98, 100, 118). Acute Q fever 
patients may also develop hepatitis (27), alone or in combination with the respiratory 
illness (99). Chronic Q fever often presents as endocarditis (41) and/or hepatitis and has 
been occasionally diagnosed in osteomyelitis cases (117, 130). An association has also 
been made between a chronic fatigue-like syndrome and Q fever (96, 122, 172, 177). 
Animal models commonly used in the study of Q fever include mice, guinea 
pigs, non-human primates, and livestock. Mice are most often utilized due to the many 
genetic and immunologic tools available, and differences in strain susceptibility have 
been noted (144). Immunocompetent mice require a large number of organisms to 
develop clinical signs of illness, and splenomegaly is recognized as the primary indicator 
of disease (38), compared to fever as the primary indicator in guinea pigs (51), which 
can develop clinical illness after intraperitoneal (IP) infection with as few as 10 
organisms (116). It has been shown that guinea pigs inoculated IP exhibit dose 
dependent fever and have more pathologic changes associated with the liver, whereas 
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those infected intranasally have greater involvement of the lungs (83). Mice are 
essentially a clearance model, relying on a mouse’s ability to control infection after 
uptake of the organism. Guinea pigs can be used as a model of clinical disease and, 
therefore, would be more relevant for testing vaccines or antibiotic regimens for human 
use.  
Guinea pigs in this study were infected with C. burnetii across a 5-log range of 
challenge doses through inhalation of small particle aerosols. These exposures resulted 
in a dose responsive relationship to clinical and pathologic changes. The disease 
produced in the guinea pig aerosol-challenge model closely mimics human acute Q fever 
and Q fever pneumonia. Experiments presented here fill gaps in the current knowledge 
concerning consequences of aerosol infection with C. burnetii using a physiologically 
relevant model, including dose response to infection, kinetics of extrapulmonary 
dissemination, and pathologic and histopathologic changes resulting from aerosol 
exposure.  
 
MATERIALS AND METHODS 
Animals. Six- to eight-week old female, outbred, Hartley guinea pigs obtained 
from Charles River Laboratories (Wilmington, MA) were housed in microisolator caging 
in a BSL-3 facility with a 12:12 light:dark cycle and were given Harlan Teklad 
(Madison, WI) guinea pig diet and water ad libitum. Guinea pigs were acclimated to the 
facility and assessment procedures for one week prior to infection to reduce stress-
related abnormalities. A modified Karnofsky performance status scoring system was 
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used to determine if humane euthanasia was necessary after infection. All animal 
experimentation was reviewed and approved by the Texas A&M University Laboratory 
Animal Care Committee and was performed in an AAALAC approved facility in 
accordance with university and federal regulations.   
Purification of C. burnetii. C. burnetii Nine Mile (RSA493), an isolate 
originating from a tick pool, was harvested from infected L929 mouse fibroblast cells by 
pooling infected cells and centrifuging at 1000 x g for 5 min. The supernatant was then 
centrifuged at 15000 x g for 30 min to collect the naturally released bacteria, and the 
resulting pellet was re-suspended in 0.25M sucrose phosphate (SP) buffer (53.9 mM 
Na2HPO4, 12.8 mM KH2PO4, 72.6 mM NaCL, 250 mM sucrose). Double distilled H2O 
was added to the original pellet. This suspension was passaged through an 18 gauge 
canula, lysis was monitored by visual inspection, and equal volumes of .25M SP were 
added when a majority of the cells were lysed. Benzonase, a non-specific nuclease 
(Novagen; Madison, WI), was added to the lysed cell suspension for 5 min at room 
temperature. Cells were re-suspended several times with a pipet before pelleting host 
cells by centrifugation at 1,000 x g for 5 min. The supernatant was combined with the 
naturally released bacteria, and the combination was pelleted by centrifugation at 14,000 
x g for 30 min. The supernatant was discarded, and the pellet was re-suspended in SP. 
Host cell debris was pelleted by centrifugation at 1,000 x g for 5 min, and the pellet was 
discarded. Bacteria in the supernatant were pelleted by centrifugation at 14,000 x g for 
30 min, the pellet was re-suspended in SP, and the purity of the bacterial pellet was 
ascertained by examination of heat fixed cells with Gimenez stain. 
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Quantification of C. burnetii inoculum. C. burnetii Nine Mile (RSA493) was 
quantified using three methods. Optical density (OD) was used to determine the number 
of particles in the stock solution as previously described (121). Particle count was 
performed using the LIVE/DEAD® BacLight™ Bacterial Viability Kit (Molecular 
Probes; Eugene, OR) according to the manufacturer’s instructions. Primers amplifying 
the com-1 gene were used to enumerate C. burnetii genome copies by real-time PCR as 
previously described (17). A dose of 2x106 organisms as determined by OD 
corresponded to 1.7x106 by particle count with 95% viability and 1.1x106 genome 
equivalents by real-time PCR. Infectious doses described in this paper are as enumerated 
by OD. 
Infection. Guinea pigs were exposed to phase I C. burnetii Nine Mile (RSA493) 
in PBS or PBS alone (negative control) using a chamber specially designed to deliver 
droplet nuclei directly to the alveolar spaces (College of Engineering Shops, University 
of Wisconsin, Madison, WI) (108, 176). This chamber allows the infection of multiple 
guinea pigs simultaneously, ensuring uniform infection within each group. 
Experimental design. 1) Fourteen guinea pigs were exposed to ~2x106 C. 
burnetii; two negative control animals were sham-infected with sterile phosphate 
buffered saline (PBS). Clinical assessment of disease progression was performed daily 
for 28 days including behavior, weight, rectal temperature, thoracic auscultation, and 
abdominal palpation. Temperatures ≥39.5°C were defined as fever. Euthanasia using a 
ketamine/xylazine overdose followed by exsanguination was performed at 7, 14, and 28 
days post-infection or as indicated by the Karnofsky score. Spleen and liver were 
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weighed at necropsy, and heart, lung (perfused), liver, spleen, and kidney were collected 
and fixed in formalin for evaluation by histopathology and immunohistochemistry.  
2) Three guinea pigs per dose were exposed to ~2x106, 2x105, 2x104, 2x103, 
2x102, or 2x101 C. burnetii based on optical density determined bacterial number 
correlation; three negative control animals were sham infected with PBS. Three 
vaccinated guinea pigs (see below) were infected with ~2x106 C. burnetii. Clinical and 
pathologic assessments were performed as described for experiment 1.   
Guinea pigs infected with 2x106 C. burnetii from experiment 2 were combined 
with those from experiment 1 to develop a survival curve. 
Vaccination. Guinea pigs were given subcutaneous injections of 100μg 
formalin-killed phase I Nine Mile C. burnetii in incomplete Freund’s adjuvant twice, 
with 2-week intervals between vaccinations and between the final vaccination and 
infection. Blood was collected from all animals prior to infection for serological 
confirmation of vaccination efficacy. 
Histopathology and immunohistochemistry. Tissues collected at necropsy 
were fixed in 10% buffered formalin for a minimum of 48 hours. Tissues were sectioned 
and embedded in paraffin, cut to a thickness of 5μm, adhered to slides, and stained 
routinely with hematoxylin and eosin. Unstained slides were prepared for 
immunohistochemical staining. Vectastain® ABC kit and Vector NovaRED substrate kit 
(Vector Laboratories; Burlingame, CA) were used with rabbit anti-Nine Mile C. burnetii 
serum generated in our laboratory for immunostaining of C. burnetii in tissue sections 
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(11); slides were counterstained with hematoxylin. All slides were evaluated in a blinded 
fashion. 
Serology. Serum samples collected at necropsy were tested by ELISA in 96-well 
U-shaped polystyrene plates (Fisher Scientific; Houston, TX) coated with 50μl of 
0.5μg/ml phase I Nine Mile C. burnetii antigen (formalin-killed whole cells) diluted in 
0.1M sodium carbonate buffer (pH 9.6) per well. After 24 h of incubation at 4ºC, plates 
were emptied and blocked for 1 h at 37ºC in 1% BSA-PBST. Serum was heat inactivated 
at 56ºC for 30 min, dilutions of 1:400 to 1:102,400 were prepared in 1% BSA-PBST, 
and 50μl of sample and 50μl of 1% BSA-PBST were added to each well and incubated 
at room temperature for 2 h. Plates were washed four times with dH2O then incubated 
with 100 μl of goat anti-guinea pig IgG (Bethyl Laboratories; Montgomery, TX) diluted 
1:1000 for 2 h at room temperature before washing again 4 times with dH2O. 100μl 
substrate (Sigma Fast ™ o-phenylenediamine dihydrochloride; Sigma-Aldrich; St. 
Louis, MO) was incubated in each well for 5-10 min in the dark at room temperature, 
and the reaction was stopped with 100μl 1M H2SO4 per well. Plates were read at 490nm 
in a Dynatech MR5000 microplate reader (Dynatech Laboratories; Chantilly, VA). 
Uninfected guinea pig serum was used as a negative control.  
Statistical analysis. Results were expressed as the means +/- the standard error 
and were compared using a student’s t-test. Differences were considered significant at 
p<0.05. 
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RESULTS 
Clinical signs of infection with C. burnetii delivered via small particle 
aerosol. Guinea pigs infected with 2x106 C. burnetii developed fever (≥39.5°C) by day 5 
post-infection (p.i.). The temperature peaked at 40.8°C on day 7 p.i. and returned to 
normal by day 13 p.i. in surviving animals. Temperature thereafter remained within 
normal parameters out to 28 days. Animals infected at all lower doses showed initial 
fever responses on later days. A dose-dependent relationship was noted for both onset 
and degree of fever (Table 2.1).  
All guinea pigs infected with 2x104-2x106 C. burnetii experienced inappetance 
and lethargy corresponding with the onset of fever. Weight loss began as early as day 4 
p.i. in 2x106 infected animals, was statistically significant (p<.01) by day 5, and 
continued to death or to day 11-13 in surviving guinea pigs (Fig. 2.1). Mild to moderate 
clinical dehydration was apparent by day 6-7 p.i. in these animals and only resolved with 
the alleviation of fever. Guinea pigs given 2x101-2x103 organisms had no significant 
weight loss or dehydration associated with disease. 
Increased respiratory rate, sounds, and effort were detected starting at days 5 and 
6 p.i. in the 2x106 infection group. Consolidation and crackles (rales) were noted on 
auscultation with uniform distribution between right and left sides. Upper respiratory 
obstruction was minimal. Paling and faint cyanosis of the muzzle was evident. Nasal 
discharge, though present, was rapidly cleaned away by the guinea pigs and therefore 
only noted sporadically throughout the main course of infection. 
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A 70.6% total mortality rate (12/17 animals from experiments 1 and 2) was noted 
in non-vaccinated guinea pigs infected with 2x106 C. burnetii, with spontaneous death 
(75%) or humane euthanasia (25%) occurring from days 7-10 p.i (Fig. 2.2); no animals 
died after 10 days post infection. Groups infected at all lower doses had no fatalities, and 
the LD50 was calculated to be 2x105.7 by the Reed and Muench method (132). 
Vaccination prior to infection conferred complete protection against the 
development of fever, respiratory abnormalities, and death. The lack of clinical signs of 
illness was comparable between the vaccinated, infected animals and those sham-
infected with PBS (Table 2.1). 
Pathologic changes in guinea pigs infected with C. burnetii. At 7 days p.i. 
guinea pigs exposed to 2x106 C. burnetii displayed complete gross consolidation of 
cranial lung lobes and partial consolidation of caudal lobes at necropsy. Several 
multifocal, pinpoint, white foci were noted throughout the lungs in both cranial and 
caudal lobes. The liver was mottled and pale with a yellowish discoloration. These 
animals also had a noticeable lack of abdominal fat. By 14 days p.i. lung consolidation 
had largely resolved in surviving guinea pigs. The liver appeared as described for 7 days 
p.i, and there was still a lack of abdominal fat. Moderate, transient splenomegaly (p 
<0.01) was also noted (Fig. 2.3). A calculation of relative spleen to body weight ratio 
also shows statistical significance (p<.05) at 7 days p.i., though this is likely artifact due 
to the rapid, severe weight loss of the animals at that time. Multifocal pinpoint to 4mm 
white foci were present in the lungs 28 days p.i. The liver continued to appear somewhat 
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mottled, but coloration returned to normal, and pinpoint to 2mm white to tan foci were 
present in some animals. 
Histopathologic evaluation (Table 2.2, Fig.2. 4) 7 days p.i. revealed a coalescing, 
panleukocytic, bronchointerstitial pneumonia (Fig. 2.4, B1-B3). Lungs were hyperemic, 
and alveolar walls were thickened due to cellular infiltration primarily consisting of 
neutrophils and lymphocytes, though all inflammatory cell types were present to some 
extent. The amount of bronchial associated lymphoid tissue (BALT) was increased (Fig. 
2.4, B1, arrows). Extensive bronchial and alveolar exudates were noted throughout the 
sections. Purulent bronchial exudates (Fig. 2.4, B2) were prominent, with degeneration 
and sloughing of the bronchial epithelial lining. Alveolar exudates (Fig. 2.4, B3) were a 
deep pink, indicating high protein content. By 28 days p.i. lung changes resolved to 
multifocal, lymphohistiocytic, interstitial pneumonia with granuloma formation (Fig. 
2.4, C1-C3). Granulomas (Fig. 2.4, C2 arrows, C3) varied in size and distribution and 
consisted primarily of aggregates of macrophages surrounded by lymphocytes.  
Severe, diffuse hepatic lipid accumulation (Fig. 2.5A) was present at 7 days p.i. 
Centrilobular hepatocellular degeneration and vacuolization were noted in the liver 
along with periportal lymphocyte infiltration and multiple small granulomas at 14 and 28 
days p.i. (Fig. 2.5B). One guinea pig evaluated at 14 days p.i. was noted to have 
extensive focal necrosis and mineralization in a section of the liver. Disruption of normal 
splenic architecture (Fig. 2.5C) was most apparent at 14 days p.i., corresponding to the 
gross splenomegaly observed at necropsy, and granulomas were present in the spleen at 
both 14 and 28 days p.i. (Fig. 2.5D). Vascular thrombi were noted in several tissues 28 
  
24
days p.i. Mineralization of kidney tubules was occasionally noted. Though some guinea 
pigs exhibited a mild lymphocytic myocarditis or pericarditis, there was no evidence of 
valvular endocarditis at any time post infection.  
Animals infected at lower doses necropsied at 28 days p.i. displayed 
progressively less severe signs of pneumonia and hepatic degeneration (Table 2.3). No 
significant pathologic changes were noted in negative control and vaccinated guinea pigs 
(Fig. 2.4, A1-A3 and D1-D3). 
Immunohistochemistry confirmed the presence of C. burnetii organisms in 
infected animals in the lungs, liver, and spleen (Table 2.3). Bacteria were most 
prominent in macrophages but were also noted in other cell types, primarily 
pneumocytes in the lungs.  
Serologic response to infection. Infected guinea pigs in all dose groups 
seroconverted by the time of euthanasia, with the exception of animals necropsied at 7 
days p.i. The extent of seroconversion was dose dependent (Table 2.1). No PBS control 
animals seroconverted.  
 
DISCUSSION 
A need exists in Coxiella research for an animal model that simulates both the 
natural route of infection and common clinical presentations associated with human 
acute Q fever infection. Such a physiologically relevant model would be valuable not 
only for testing vaccines and therapeutic agents but also in evaluating the comparative 
virulence of different C. burnetii isolates. Moos and Hackstadt showed a difference in 
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virulence between two isolates, Nine Mile and Priscilla, in an IP challenge guinea pig 
model (116), and Kazar, et al., also demonstrated a lower virulence of Priscilla compared 
to the Nine Mile and S isolates (71). No histologic changes were described by Stein, et 
al., for Q212 infected mice as compared to multiple pathologic changes in Nine Mile 
infected animals (154).  The guinea pig aerosol-challenge model described here is able 
to discern differences in disease manifestation within and between the six C. burnetii 
genomic groups (manuscript in preparation). This model would also be useful for 
examining the kinetics of extrapulmonary distribution of C. burnetii, especially in whole 
blood and serum, in very early stages of infection for the purposes of improving 
diagnostic tests for use in humans following a suspected exposure or outbreak. 
The dose responsive nature of infection in the guinea pig aerosol-challenge 
model was expected and consistent within each group. This clinical dose-response effect 
has been previously noted in humans (13, 101) and cynomolgus macaques (46). Guinea 
pigs receiving lower numbers of organisms took longer to develop a lower grade fever 
for a brief period of time, in some cases as little as one day. Conversely, guinea pigs 
receiving larger numbers of organisms developed a high fever which persisted longer. 
Fatalities noted in animals exposed to 2x106 C. burnetii were likely due to severe 
respiratory insufficiency. Guinea pigs receiving 2x103-2x105 organisms, though also 
experiencing respiratory difficulty and showing histologic evidence of pneumonia, were 
able to overcome the illness. An LD50 of 2x105.7 C. burnetii was determined in this 
model. The aerosol-challenge mouse model described by Stein, et al., required 108 C. 
burnetii before any pathologic changes were noted at early time points post infection and 
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asserts that a large amount of the organism must be present in aerosols for the 
development of Q fever (154), whereas the guinea pig model displays clinical and 
pathologic evidence of Q fever over a wider and lower range of doses at more time-
points post infection, and the consistent development of fever, easily measurable 
antemortem, makes the guinea pig a much more sensitive model. As opposed to reports 
using high doses of C. burnetii for infection via inhalation in guinea pigs (83), this study 
showed that guinea pigs exposed to as few as 2x101 organisms are able to develop acute 
Q fever, as is the case in humans.  
 The histologic characteristics of the pneumonia which developed in the guinea 
pigs in this study corresponded to those seen in human Q fever pneumonia (98, 100, 
118). The change from the panleukocytic bronchointerstitial pneumonia seen 7 days p.i. 
in 2x106 infected animals to a lymphohistiocytic or granulomatous pneumonia by 28 
days p.i. showed resolution of the pneumonia and recovery, but it is unknown at this 
time how long the pulmonary (and hepatic) granulomas may persist post-infection. 
Should these granulomas remain with viable organisms, it is possible that they could be 
sites of persistent or latent infection, like the placenta (130), bone marrow (97), and liver 
(50) in humans. 
 In many animals, hepatic lipidosis has been associated with periods of anorexia, 
similar to that seen in guinea pigs infected at higher doses in this study, leading to an 
excess of triglycerides in the liver, intrahepatic cholestasis, and liver failure. Guinea pigs 
are known to develop fatty liver as a result of reduced carbohydrate intake and 
mobilization of fat as an energy source, most often associated with fasting metabolic 
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pregnancy toxemia (141). The hepatic steatosis seen at 7 days p.i. in our guinea pigs 
infected via aerosol with 2x106 C. burnetii has been previously reported in IP inoculated 
guinea pigs 3-4 days p.i. An increase in triglycerides, unesterified fatty acids, and 
cholesterol have been noted during early Q fever infection in these animals, and it is 
thought that the development of fatty liver is due to failure of the liver to export these 
lipids after their mobilization to the liver (15). An association has also been suggested 
between fatty liver development and changes in the plasma membrane peptide 
composition, which alters lipid transport (92). This steatohepatitis resolved after the 
main course of infection when the animals resumed eating and was no longer apparent at 
14 and 28 days p.i. when centrilobular hepatocellular degeneration and vacuolization 
were noted. Centrilobular hepatic degeneration is a zonal change centered about the 
central vein (hepatic venule) and is generally caused by low oxygen tension or high 
concentration of enzymes associated with bioactivation of toxic compounds. Low 
oxygen tension, in this case, could be caused by the severe respiratory insufficiency and 
resulting hypoxia displayed by high-dose infected guinea pigs.  
 There is currently no licensed vaccine against Q fever in the United States, 
although a killed whole cell vaccine (QVax, CLS Ltd.) available in Australia has been 
shown to be highly successful in the prevention of clinical disease in humans (66) as 
well as in rodent (168) and non-human primate (169) models. However, this vaccine can 
cause severe necrotic lesions or granuloma development at the injection site in humans 
previously exposed to C. burnetii (36, 94), which requires skin testing prior to 
vaccination. A new, efficacious vaccine without such deleterious side effects is needed, 
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and appropriate animal models of human Q fever will be required to evaluate the safety 
and efficacy of new vaccine candidates. Guinea pigs in this study that were vaccinated 
with whole killed cells were completely protected from fever development and death 
when given a high dose challenge, again correlating with human response to vaccination 
and challenge (1). The guinea pig aerosol-challenge model presented here mimics both 
the clinical and pathologic changes seen in human acute Q fever and Q fever pneumonia 
cases and will provide an accurate and valuable tool for the study of the general 
pathogenesis of C. burnetii infection, vaccine assessment, and evaluation of host 
immune responses. 
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III. GENOGROUP-SPECIFIC VARIATIONS IN DISEASE POTENTIAL OF 
COXIELLA BURNETII ISOLATES IN A GUINEA PIG AEROSOL-
CHALLENGE MODEL OF ACUTE Q FEVER 
 
INTRODUCTION 
Coxiella burnetii, the etiologic agent of acute and chronic Q fever, is an obligate 
intracellular bacterium of worldwide distribution with a diverse host range. Livestock 
infected with C. burnetii may be asymptomatic carriers or exhibit reproductive disorders 
and serve as the organism’s primary reservoir. Humans are most often infected through 
inhalation of the bacterium in fine-particle aerosols, though transmission may also occur 
through ingestion of the organism from contaminated, unpasteurized, dairy products (63, 
86). Humans can become ill from exposure to as few as 10 organisms (13) and may 
display signs of: 1) an acute flu-like illness with or without pneumonia and/or hepatitis 
(98, 99); or 2) a chronic endocarditis and/or hepatitis (129, 130).  
 C. burnetii isolates have been obtained from natural Q fever infections in humans 
and other animals. Several theories have been proposed to explain the dichotomy in 
development of acute or chronic Q fever. One hypothesis is that unique genome 
sequence differences between genomic groups correlate with the clinical expression of Q 
fever (140). Biochemical markers have grouped C. burnetii isolates from chronic disease 
patients separately from acute disease/arthropod/domestic animal isolates, but whether 
these groupings predict virulence potential and acute/chronic disease outcome has not 
  
30
 
yet been fully resolved. Samuel, et al., were the first to separate these isolates and their 
resulting diseases based on plasmid patterns (140). Hackstadt used variations in LPS 
banding patterns to divide isolates of C. burnetii into 3 groups, and group distinction was 
noted in correlation with acute or chronic disease (47).  Hendrix, Samuel, and Mallavia 
separated C. burnetii isolates into six genomic groups (55). Group I-III isolates have a 
QpH1 plasmid and have been isolated from ticks, acute human Q fever cases, cow’s 
milk, and livestock abortions. Groups IV and V have a QpRS plasmid or no plasmid, 
respectively, and have been associated with livestock abortions and human chronic 
endocarditis or hepatitis. Group VI isolates were collected from wild rodents in Dugway, 
Utah, and are considered infectious but avirulent (158, 159). Jager, et al., used restriction 
fragment length polymorphism (RFLP) to differentiate 80 C. burnetii isolates and 
reproduced distinguished patterns for reference isolates in groups I, IV, V, and VI (67). 
More recently, multiple locus variable nucleotide tandem repeat (VNTR) analyses 
(MLVA) (161) have validated these groupings. A comprehensive microarray- based 
whole genome comparison by Beare, et al., confirmed the relatedness of RFLP-grouped 
isolates and added two more genomic groups, VII and VIII (12). Infrequent restriction 
site-PCR (IRS-PCR) of 14 livestock and tick isolates resulted in six groups; subsequent 
MLVA typing of 42 isolates revealed 36 genotypes (5). Glazunova, et al., used 
multispacer sequence typing (MST) to analyze 173 isolates, a majority of which were 
acquired from chronic disease patients, and identified thirty genotypes in three 
monophyletic groups; an association between plasmid type, some genotypes, and disease 
type was observed (45). These monophyletic groups supported the early RFLP groups 
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and placed group I, II, and III as one monophyletic group, group IV representative of the 
second monophyletic group, and group V representative of the third monophyletic 
group. It has been shown in an intraperitoneal (IP) challenge guinea pig model that while 
only 101 organisms of the acute-disease-associated group I isolate RSA493 caused fever, 
106 chronic-disease-associated group IV isolate Q177 organisms were required for fever 
development (116). In opposition to the theory of genotype/pathotype correlation, Stein 
and Raoult evaluated 28 human isolates and found that isolates bearing the QpH1 
plasmid were present in both acute and chronic Q fever patients in France, and isolates 
without the QpH1 plasmid were able to cause acute disease (155). QpH1 plasmid-
containing isolates have also been isolated from chronic endocarditis patients (162). 
 Several groups have speculated that host factors are primarily responsible for the 
outcome of infection with C. burnetii. Individual differences in immune function and 
competence lead to varying sensitivity to infection and disease development. In this 
case, acute and chronic disease could be caused by the same isolate, and chronic disease 
would develop because of compromised resistance of the host rather than any specific 
property of the pathogen. It is known that HIV infection is a risk factor for the 
development of chronic Q fever endocarditis (19, 90). Deficiencies in the host specific 
cell-mediated immune response have been associated with the suppression of monocyte 
and macrophage activity (77), and monocytes from chronic Q fever patients are known 
to have defective phagosome maturation and impaired C. burnetii killing, regulated by 
IL-10 (44).  There is strong evidence to support the role of increased host production of 
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interleukin-10 in the development of chronic Q fever endocarditis and fatigue syndrome 
(25, 42, 58, 122). 
Route of infection may also be a determining factor in the manifestation of acute 
or chronic Q fever. LaScola and Marrie demonstrated that the route of infection and size 
of inoculum affect clinical illness and pathology associated with infection in mouse and 
guinea pig models (83, 102). Differences in the geographic distribution of disease have 
also been noted (100); in Nova Scotia the primary manifestation of acute Q fever is 
pneumonia (107), but in France it is hepatitis, possibly due to ingestion of raw milk 
(164). 
 The establishment of the aerosol model of C. burnetii infection in guinea pigs 
(137) provides a relevant model in which to test isolate virulence. Eight isolates from 
four genomic groups (Table 3.1) were evaluated for their ability to cause acute disease. 
We hypothesized that isolates within the same genotypic group would cause similar 
disease and that there would be a distinct difference in disease manifestation between 
isolate groups. Lesny, et al., compared the cross-immunity of whole-cell and soluble Q 
fever vaccines made from phase I Nine Mile, S, Priscilla, and Luga strains. They found 
that vaccines from Nine Mile and Priscilla afforded a higher degree of protection than S 
and Luga vaccines and that whole-cell vaccines were more effective than soluble 
vaccines (87).We also evaluated the potential protection of a vaccine made against one 
C. burnetii isolate in protecting against infection with an isolate from another group. We 
speculated that such a vaccine would confer heterologous protection against virulent 
high-dose challenge. 
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MATERIALS AND METHODS 
Animals. Female Hartley guinea pigs (Charles River Laboratories; Wilmington, 
MA) weighing approximately 350-450g were housed in an approved BSL-3 facility 
under microisolator caging and a 12:12 light:dark cycle and were provided with Harlan 
Teklad guinea pig diet (Madison, WI) and water ad libitum. All guinea pigs used in this 
study were acclimated to the facility and assessment procedures during the week prior to 
infection to decrease stress-related abnormalities. Texas A&M University Laboratory 
Animal Care Committee reviewed and approved all animal experimentation, which was 
performed in AAALAC approved facilities in accordance with university and federal 
regulations.   
Purification and quantification of C. burnetii. C. burnetii Nine Mile (RSA493) 
and S (Q217) isolates were harvested from infected L929 mouse fibroblast cells as 
previously described (137). C. burnetii African (RSA334), Ohio 314 (RSA270), MSU 
Goat (Priscilla) (Q177), P (Q173), G (Q212), and Dugway (5J108-111) isolates were 
purified from infected yolk sacs as formerly reported (54, 140). 
C. burnetii was quantified by optical density (121), direct viable particle count 
using the LIVE/DEAD® BacLight™ Bacterial Viability Kit (Molecular Probes; Eugene, 
OR), and quantitative real-time PCR (qPCR) using primers amplifying the com-1 gene 
(17) (Table 3.2). 
Experimental design. A chamber specially designed to deliver droplet nuclei 
directly to the alveolar spaces (College of Engineering Shops, University of Wisconsin, 
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Madison, WI), allowing the infection of multiple guinea pigs simultaneously and 
ensuring uniform infection within each challenge group (108, 176), (137), was used for 
all infection studies. 
Three guinea pigs per group were infected with low, mid, or high doses of one of 
the following phase I C. burnetii isolates (Table 3.1): Nine Mile RSA 493, African 
RSA334, Ohio 314 RSA270, MSU Goat (Priscilla) Q177, P Q173, G Q212, S Q217, or 
Dugway 5J108-111. Four negative control animals were sham-infected with sterile 
phosphate buffered saline (PBS). Guinea pig health was assessed by a veterinarian daily. 
Weight, rectal temperature, and behavioral attitude were recorded along with any 
abnormalities noted on thoracic auscultation and abdominal palpation. A rectal 
temperature ≥39.5°C was defined as fever. Guinea pigs were euthanized with a 
ketamine/xylazine overdose followed by exsanguination 28 days post infection (p.i.). 
Spleen and liver were weighed at necropsy. These and other tissues were collected and 
fixed in 10% buffered formalin for histopathologic evaluation. Serum was obtained from 
each animal for serologic testing. 
In a separate experiment, three guinea pigs per group were exposed to PBS or 
high-dose RSA493, Q173, Q212, or 5J108-111. Daily assessment of these animals was 
performed as described above, and organs were weighed at necropsy 14 days p.i. to 
detect splenomegaly and/or hepatomegaly. 
In the heterologous protection study, guinea pigs were vaccinated with 40μg of 
formalin-inactivated phase I C. burnetii Nine Mile RSA493 or S Q217 in Freund’s 
incomplete adjuvant or adjuvant alone twice, with two week intervals between 
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vaccinations and infection. Animals were then infected with high doses of either Nine 
Mile RSA493 or S Q217. Three animals per group were separated into the following six 
groups: 1) non-vaccinated, RSA493 infected; 2) non-vaccinated, Q217 infected; 3) 
RSA493 vaccinated, RSA493 infected; 4) Q217 vaccinated, Q217 infected; 5) RSA493 
vaccinated, Q217 infected; and 6) Q217 vaccinated, RSA493 infected. Guinea pigs were 
monitored for 14 days p.i. for development of fever and other clinical signs of illness. 
Histopathology and immunohistochemistry. Formalin fixed tissue samples 
from the high-dose infection group of each isolate were sectioned and embedded in 
paraffin, cut to a thickness of 5μm, adhered to slides, and routinely stained with 
hematoxylin and eosin. Unstained slides were prepared for immunohistochemistry on 
which Vectastain® ABC kit and Vector NovaRED substrate kit (Vector Laboratories; 
Burlingame, CA) were used with in-house generated rabbit anti-Nine Mile C. burnetii 
for immunostaining of C. burnetii in tissue sections (11). Slides were counterstained 
with hematoxylin. All slides were evaluated in a blinded fashion. 
Serology. Serum samples collected at necropsy were tested by ELISA in 96-well 
U-shaped polystyrene plates (Fisher Scientific; Houston, TX) coated with 50μl of 
1.5μg/ml phase I Nine Mile C. burnetii antigen diluted in 0.1M sodium carbonate buffer 
(pH 9.6) per well. After 24 h of incubation at 4ºC, plates were emptied and blocked for 1 
h at 37ºC in 1% BSA-PBST. Serum was heat inactivated at 56ºC for 30 min, dilutions of 
1:400 to 1:102,400 were prepared in 1% BSA-PBST, and 50μl of sample and 50μl of 1% 
BSA-PBST were added to each well and incubated at room temperature for 2 h. Plates 
were washed four times with dH2O then incubated with 100 μl of goat anti-guinea pig 
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IgG (Bethyl Laboratories; Montgomery, TX) diluted 1:1000 for 2 h at room temperature 
before washing again 4 times with dH2O. 100μl substrate (Sigma Fast ™ o-
phenylenediamine dihydrochloride; Sigma-Aldrich; St. Louis, MO) was incubated in 
each well for 5-10 min in the dark at room temperature, and the reaction was stopped 
with 100μl 1M H2SO4 per well. Plates were read at 490nm in a Dynatech MR5000 
microplate reader (Dynatech Laboratories; Chantilly, VA). Serum from uninfected 
guinea pigs was used as a negative control.  
Statistical analysis. Results were expressed as the means +/- the standard error 
and were compared using a student’s t-test. Differences were considered significant at 
p<0.05. 
 
RESULTS 
 Group I and V C. burnetii isolates cause acute Q fever and Q fever 
pneumonia in the guinea pig model. Guinea pigs challenged with group I and V 
isolates developed a significant fever in response to infection (p<0.01), whereas those 
given isolates from groups IV and VI were afebrile even at the highest challenge dose 
(Table 3.3, Fig. 3.1).  
Fever response, weight loss, and other clinical signs displayed a dose dependent 
relationship in guinea pigs infected with group I C. burnetii isolates RSA334 and 
RSA270 as has been described for the reference isolate in this group, RSA493 (137). All 
animals receiving high-dose RSA334 or RSA270 organisms died within 7-9 days post 
infection, as did 2/3 receiving RSA493; lower infectious doses were not lethal. Gross 
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lung consolidation and overall lack of normal body fat were noted on necropsy at 7-9 
days p.i. in guinea pigs infected with the highest dose of organisms. Histologically, these 
animals had severe panleukocytic bronchointerstitial pneumonia with bronchial and 
alveolar exudates. Lung tissues from the surviving RSA493-infected guinea pig and 
those given the mid-dose group I organisms were evaluated at 28 days p.i. for 
comparison to animals infected with other isolates evaluated at this time-point. Grossly, 
multiple small white foci were noted in right and left lung lobes; moderate multifocal 
lymphohistiocytic pneumonia with granuloma formation was present in lung sections.  
 No significant fever or other overt clinical signs were noted in guinea pigs 
infected with group IV isolates Q177 and Q173. Mild lymphohistiocytic pneumonia was 
seen histologically in animals delivered the highest dose of organism. 
 Group V isolate Q212- and Q217-infected guinea pigs all developed fever when 
delivered the highest challenge dose, and dose-dependent temperature increase and other 
clinical signs were again noted, with no fever development in those animals receiving 
the lowest dose of organism. Though auscultation confirmed respiratory compromise, 
none of the infections were lethal. At 28 days p.i., the lungs had a mild to moderate 
lymphohistiocytic interstitial pneumonia, and small granulomas were occasionally noted.  
 No major clinical or pathologic changes were noted in negative control animals 
or in guinea pigs infected with the group VI isolate, 5J108-111. Table 4 compares the 
severity of histopathologic changes in guinea pigs infected with high dose C. burnetii 
isolates from each group at 28 days p.i. Immunohistochemistry confirmed the presence 
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of C. burnetii organisms, primarily in macrophages, in the lungs, liver, and spleen of 
high-dose infected animals.  
Splenomegaly in response to C. burnetii infection. There were no significant 
differences in spleen weight at 28 days p.i. within or between genomic or dose groups. 
Animals infected with all isolates examined at 14 days p.i. (RSA493, Q173, Q212, and 
5J108-111) had significantly larger spleens than PBS control animals, and spleens from 
RSA493 and Q212 guinea pigs were significantly larger (p<0.01 and p<0.05, 
respectively) than those of Q173 and 5J108-111 animals (Fig. 3.2). Pathologic findings 
included multiple small granulomas in the spleens of group I-infected guinea pigs; fewer 
small granulomas were occasionally noted in animals infected with group IV and V 
isolates. 
Increased incidence and severity of hepatitis in group IV infected guinea 
pigs. The characteristic doughnut granulomas of human acute Q fever hepatitis (99) have 
not been previously described in animal infection experiments and were likewise not 
seen in guinea pigs infected in this study. RSA 493, RSA334, and RSA270 (group I) 
liver sections showed a mild hepatitis and severe hepatic lipidosis at death 7 days p.i. 
Tissue sections from the remaining RSA493 guinea pig and those infected with the mid-
dose group I organisms were evaluated for comparison with animals infected with other 
isolates at 28 days p.i. Few pinpoint white to tan foci were present on the surface of the 
liver and histologically exhibited centrilobular hepatocellular degeneration and 
vacuolization, periportal lymphocyte infiltration, and multiple small granulomas 
consisting primarily of lymphocytes with few macrophages.  
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Few pinpoint to 4mm tan to white foci, singly and coalescing, were observed on 
the liver surface of guinea pigs infected with group IV isolates Q177 and Q173 (Fig. 
3.3A), and periportal lymphocytic infiltration and multiple granulomas of varying sizes 
were noted histologically. These granulomas were more defined and had a greater 
amount of histiocytic involvement than those seen in guinea pigs infected with group I 
isolates. Subjectively, of all animals necropsied from each isolate group, hepatic 
granulomas from those infected with Q173 were the greatest in size and number (Fig. 
3.3B).  
Few small granulomas and infiltration of lymphocytes along portal tracts were 
noted in the livers of group V isolate Q212- and Q217-infected guinea pigs, and the 
degree of hepatic change indicated that isolates from this group are more hepatovirulent 
than group I isolates but less than group IV isolates.  
Necrotic lesions were associated especially with peripheral granulomas in guinea 
pigs infected with isolates from groups I, IV, and V, and were again most common in 
animals given group IV isolates. No hepatic granulomas were noted in guinea pigs 
infected with the group VI isolate 5J108-111. Liver weights did not vary significantly 
within or between genomic groups.  
Gallstone formation associated with C. burnetii infection. Gallstones were 
present in five guinea pigs from the following groups: mid-dose RSA270, mid- and 
high-dose Q177, low-dose Q173, and low-dose 5J108-111. The biliary calculi were the 
size of sand and were black (pigment) in RSA270, Q177, and Q173; white (cholesterol) 
in 5J108-111; and mixed black and white in Q177.  
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Serologic response to infection. Infected guinea pigs in all dose groups for each 
isolate had seroconverted by the time of euthanasia, with the exception of high-dose 
infected RSA493, RSA334, and RSA270 animals necropsied at one week p.i. and low-
dose 5J108-111 infected guinea pigs (Table 3.3). The degree of seroconversion was dose 
dependent and varied among isolates (data not shown). No PBS control animals 
seroconverted.  
Heterologous protection of cross vaccination and challenge. Guinea pigs were 
given RSA493 or Q217 vaccines and cross-challenged to evaluate the potential 
heterologous protection against high-dose infection. Non-vaccinated guinea pigs 
developed a noticeable fever response by day 5 p.i., and infection was lethal in 3/3 
RSA493 and 1/3 Q217 challenged animals. Guinea pigs vaccinated with either formalin-
killed RSA493 or Q217 were completely protected against fever development and death 
when challenged with either RSA493 or Q217 (Fig. 3.4). 
 
DISCUSSION 
The ability to cause fever and respiratory illness was isolate and dose dependent 
in the guinea pig aerosol-challenge model, with isolates from groups I and V exhibiting 
disease consistent with human acute Q fever. Isolates within the same genomic group 
produced similar clinical illness, strongly supporting the hypothesis that genogroup-
specific genetic differences in the bacterial isolates do play a role in virulence. It was 
shown here that isolates associated with chronic disease, Q212 and Q 217, have the 
ability to cause acute disease in the guinea pig model. These group V isolates have no 
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plasmid, though a portion of the QpRS plasmid of genogroup IV has been integrated into 
their genome (140). This is interesting in that the clinical illness produced by these 
isolates lay somewhere between what was seen with group I and group IV isolates, 
suggesting the genetic differences in virulence are not plasmid related, but plasmid 
groupings can be used to anticipate the expected disease occurrence in a given outbreak. 
Although C. burnetii isolates are considered to belong to a single species according to 
serologic methods and sequence analysis of 16S rRNA (155), data presented in this 
study emphasize that the genetic diversity among isolates correlates with disease 
manifestation. Our study confirmed and expanded the observations by Kazar, et. al., as 
to the greater virulence of Nine Mile and S isolates compared to that of Priscilla (71).  
Phase variation is the only well characterized phenotypic difference that relates 
to virulence in C. burnetii (160). Although LPS may be a major virulence determinant, 
other components alone or in association with LPS may be responsible for differences in 
fever development in aerosol-challenged guinea pigs. The combination of a variety of 
factors expressed by phase I bacteria likely govern the ability of C. burnetii to infect 
cells and maintain continuous growth within the phagolysosome. A recent report 
compared all open reading frames (ORF) of Nine Mile phase I to African RSA334, Ohio 
314 RSA270, P Q173, G Q212, S Q217, and Dugway, among others (12), and a majority 
of the ORFs deleted from Nine Mile in the other isolates were either hypothetical or 
nonfunctional; however, a few were associated with assorted cellular functions. 
Based on the persistent presence of the antigen in humans during chronic Q 
fever, host factors could be an important determinant in the development of chronic 
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disease. Findings of this study do not preclude the importance of host factors in causing 
disease as only immunocompetent animals were used for challenge. Immunodeficient 
animals may develop acute disease from infection with group IV and VI isolates that 
were unable to produce clinical signs of illness in the model presented.  It has been 
shown that humans who are immunocompromised are more prone to develop chronic 
disease (128), but whether host factors or the genetic properties of the pathogen play a 
more important role is not yet clear. It is likely that chronic Q fever results from a 
complex combination of patient predisposition and infection with specific C. burnetii 
isolates. In a previously reported study, severe combined immunodeficient (SCID) mice 
infected with C. burnetii Nine Mile RSA493 (genomic group I) showed severe lesions 
consistent with those seen in chronic Q fever (3). These findings indicate that this 
isolate, which is typically associated with acute disease, can induce chronic disease 
lesions in the absence of a normal immune response. Humans that have recovered from 
acute Q fever can remain latently infected, and it is possible that patients develop 
chronic disease because the organism continues to multiply in various organs (184). As 
the experimental infection of guinea pigs with various isolates in our study was only 
conducted out to 28 days p.i., it was a measure of the potential to cause acute disease 
only. Further studies must be conducted on the ability of each isolate to induce chronic 
disease and on disease manifestation in immunocompetent vs. immunodeficient animals. 
Killed whole cell vaccines made from isolates differing in LPS banding pattern 
(47), plasmid type (140), and genomic group (55), specifically isolates from groups I and 
V, confer heterologous protection against virulent high dose challenge in accordance 
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with previous studies (87). This suggests that although the manifestation of disease may 
differ among various isolate groups, the antigenic properties of whole cell vaccines are 
similar enough that cross protection is possible. This could be of utmost importance in 
offering reliable protection in the event of an outbreak.  
The differences in infectious dose noted when OD, particle count, and genome 
copy enumeration were compared underline the importance of using multiple 
quantitation methods. Some of the differences in disease manifestation seen in this study 
could be due to slight differences in infectious dose delivered. For instance, Q177 and 
Q173 both induced hepatic changes, though guinea pigs infected with Q173 appeared to 
induce more severe lesions than Q177, which had a lower infectious dose by OD and 
qPCR. The difference in infectious dose as determined by genome copy number could 
account for this variation. However, Q212 and Q217 both caused fever, and although 
guinea pigs infected with Q212 did not attain the same degree of febrile response as 
Q217 infected animals, quantitation by particle count and real-time PCR showed 
infectious doses of Q217 to be over a log lower than Q212. It could be argued that Q177 
infected guinea pigs did not develop fever because fewer bacteria were present in the 
aerosol challenge; however the group IV isolates did not induce fever at any of the 
challenge doses while group I isolates induced fever even at the lowest dose. We believe 
that despite the occasional variation in infectious dose depending on enumeration 
technique, the significant differences noted among genotypic groups are valid. 
Splenomegaly has long been associated with virulent C. burnetii infection in 
animal models (38), possibly due to excessive antigenic stimulation. The lack of a 
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statistically significant difference in spleen and liver weights among animals infected 
with different doses and isolates at 28 days p.i. is likely due to the time at which animals 
were necropsied post infection. We have previously found that splenomegaly in the 
aerosol-challenge guinea pig model is transient and peaks around 14 days post infection 
in animals given 106 Nine Mile C. burnetii (137), resolving by the 28-day time point 
used as the termination point for this study. An endpoint of 28 days was initially chosen 
since fever was used as the primary indicator of disease, and it has been determined in 
previous studies that lower doses of virulent organisms take longer to induce fever; it 
was possible that less virulent isolates could take even longer. By examining animals 
infected with select isolates at 14 days p.i., differences in spleen size were discovered. 
Splenomegaly was noted to some degree in all infected guinea pigs and was significantly 
greater in those infected with isolates that also induced a fever response, representing yet 
another difference in virulence among genogroups. It was the desire of the authors to 
have quantitative PCR counts of C. burnetii from splenic tissue to correlate to the 
observed splenomegaly, as has been done in the mouse model (unpublished data); 
however, due to as yet unresolved technical issues in the extraction process, this was not 
possible at this time. 
The presence of gallstones may be an incidental finding due to the occasional 
occurrence of this condition in guinea pigs, though it is generally only noted in aged 
animals (103). However, as gall bladder disease in the form of acute acalculous 
cholecystitis has been shown to occur in humans in connection with C. burnetii infection 
(115, 135), it is possible that infection with C. burnetii contributed to the development of 
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cholelithiasis in this study. Elevated cholesterol enhances stone formation in the guinea 
pig gallbladder (69), and recently C. burnetii infection has been reported to lead to an 
increase in cellular cholesterol and transcriptional up-regulation of host cholesterol 
trafficking and biosynthesis genes (61), suggesting another possible explanation for 
gallstone formation in association with C. burnetii infection. It is interesting to note that 
in the author’s experience, though cholelithiasis was found in 5/63 guinea pigs infected 
with various other C. burnetii isolates in this study, it has not yet been found in over 100 
guinea pigs infected with Nine Mile isolate alone. Similar findings have occurred in 
other rodents where certain species of Helicobacter have been identified as 
cholelithogenic, whereas others have no effect on gallstone development. It has been 
proposed that the formation of cholesterol gallstones may be due to species-specific 
bacterial products or an immunologic response of the host to infection (104). 
Isolates of phase I C. burnetii have the potential to cause a range of clinical signs, 
including fever, pneumonia, hepatitis, and splenomegaly. Isolates from one human 
chronic disease group induced mild to moderate acute disease in the guinea pig aerosol-
challenge model while a separate isolate group representing several chronic disease 
isolates caused no acute disease. In this study, isolates within the same genomic group 
caused similar pathologic responses, with a distinction in strain virulence between 
established genomic groups, sustaining the theory that genetic differences in the 
bacterial isolates do affect their virulence.  
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IV. IMMUNOLOGY OF COXIELLA BURNETII INFECTION AND 
 
 PROTECTIVE VACCINATION 
 
 
INTRODUCTION 
Q fever is a zoonotic disease with worldwide distribution caused by the obligate 
intracellular bacterium Coxiella burnetii. Infection may be subclinical, acute, or chronic. 
Acute illness can develop from exposure to as few as 10 organisms (13) and is most 
commonly characterized by a self-limiting, flu-like illness with high fever and 
periorbital headache that may develop into a pneumonia. Chronic disease may present as 
endocarditis, hepatitis, or a chronic-fatigue-like syndrome. The disparity in the 
development of acute or chronic Q fever may be due to unique virulence differences 
between genomic groups, host factors involving individual differences in immune 
function, or a combination of the two. Vaccination with a killed whole cell vaccine (Q-
Vax, CLS Ltd.; Australia) made from virulent phase I C. burnetii is successful in 
preventing clinical disease in humans (66) as well as in rodent (168) and non-human 
primate (169) models; vaccines made from avirulent phase II organisms are less 
effective (120).  
The cell-mediated immune response (CMI) is considered essential for the control 
of Q fever infection, although humoral immunity may accelerate the process (64). 
Deficiencies in the host-specific CMI have been associated with the suppression of 
monocyte and macrophage activity (77). Comparatively little has been reported on the 
host immune response to acute infection with C. burnetii compared to that of chronic 
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infection. In one study, patients with uncomplicated acute Q fever had an increased 
release of tumor necrosis factor (TNF), interleukin-6 (IL-6), IL-12, and IL-10 compared 
to chronic endocarditis patients, with a greater increase in acute Q fever hepatitis 
patients than in those presenting with fever or pneumonia (58). Another report indicated 
an increase in TNF and IL-6 but not IL-1β in acute Q fever and Q fever endocarditis, 
with an increase in IL-1 receptor agonist  (IL-1Ra) and TNF receptor type II in patients 
with the acute disease (23). It was speculated that this decrease in IL-1β and increase in 
IL-1Ra may contribute to decreased resistance to C. burnetii infection. In blood cell 
cultures from healthy donors stimulated with antigens of either Nine Mile or Priscilla 
strain C. burnetii, it was shown that Nine Mile exhibited less cytokine-inducing activity 
with respect to TNF-α, IL-6, and IL-8 than Priscilla, but had a greater inhibitory effect 
on IL-1β and IFN-γ secretion (81). Several reports have shown a strong correlation 
between increased host production of interleukin-10 in the development of chronic Q 
fever endocarditis and fatigue syndrome (25, 42, 58, 122) Increases in transforming 
growth factor-beta (TGF-β) have also been associated with Q fever endocarditis and 
chronic fatigue syndrome (25, 122). 
Suppression of lymphoproliferation has been reported following both acute and 
chronic infection (75, 171) due to the production of prostaglandin E2 (PGE2) by 
stimulated monocytes (77). Vaccination with phase I. C. burnetii results in an increase in 
the blastogenic response (65, 74, 179). 
The purpose of this study was to characterize the host immune responses to acute 
Q fever infection by systematic evaluation of cytokine and chemokine profiles in a 
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clinically relevant model. We evaluated the immune response of guinea pigs infected via 
aerosol with a sub-lethal challenge of C. burnetii at 7, 14, and 28 days post infection, 
corresponding to early, late, and convalescent acute disease. Lymphoproliferative 
response was assessed, and message RNA was measured for IFN-γ, TNF-α, TGF-β, 
RANTES, IL-1β, IL-8, IL-10, and IL-12p40 in response to infection. An effort was then 
made to discern differences between protective phase I and non-protective phase II 
vaccination strategies that were established in a mouse model (GQ Zhang, manuscript in 
preparation). Once the baseline responses were determined for the reference isolate, 
Nine Mile RSA493, we sought to discriminate between the lymphoproliferative 
responses of a selection of isolates previously demonstrating differing virulence and 
disease outcomes after aerosol challenge. 
 
MATERIALS AND METHODS 
Bacteria. C. burnetii Nine Mile RSA493 was harvested and purified from 
infected L929 mouse fibroblast cells as described (137); P Q173, G Q212, and Dugway 
5J108-111 isolates were purified from infected yolk sacs as formerly reported (54, 140). 
C. burnetii was quantified by optical density (121), particle count using the 
LIVE/DEAD® BacLight™ Bacterial Viability Kit (Molecular Probes; Eugene, OR), and 
genome copy number using quantitative real-time PCR (qPCR) com-1 gene primers(17). 
Animals. 350-450g female Hartley guinea pigs (Charles River Laboratories; 
Wilmington, MA) were housed in microisolator caging with a 12:12 light:dark cycle and 
were provided with Harlan Teklad guinea pig diet (Madison, WI) and water ad libitum. 
All guinea pigs used in this study were acclimated to the facility and assessment 
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procedures during the week prior to infection to decrease stress-related abnormalities. 
Infected animals were housed in an approved BSL-3 facility. The University Laboratory 
Animal Care Committee of Texas A&M University reviewed and approved all animal 
experimentation, which was performed in AAALAC approved facilities in accordance 
with university and federal regulations.  
C. burnetii antigen preparations. Formalin-killed phase I (WCV-I) and phase II 
(WCV-II) Nine Mile C. burnetii were prepared for use in vaccination and in vitro 
antigenic stimulation by inactivating live organisms in a 1% formalin solution for 48 h. 
The product was then dialyzed against phosphate buffered saline (PBS) for 48 hours 
with 4 changes of PBS. Additional C. burnetii antigens were developed to determine the 
optimum antigen for use in lymphoproliferation assays. Samples were frozen in liquid 
nitrogen for 1 min, thawed in a 37°C water bath for 1 min, then disrupted using 
FastProtein Blue Matrix in a FastPrep instrument (Q-biogene, Irvine, CA) according to 
manufacturer’s instructions, and the resulting supernatant was collected. This cycle was 
repeated 3 times, and the supernatants were pooled. The final pellet from this procedure 
was then extracted by detergent treatment. The pellet was re-suspended with 2% 
weight/volume N-lauroylsarcosine (Sigma, St. Louis, MO) in dH2O and mixed for 1 h. 
The supernatant was collected after 5 min of centrifugation at 13,000 x g and dialyzed 
against dH20 for 12 h and 3 water changes. The final product was then combined 1:1 
with the soluble antigen obtained from the FastPrep homogenization. 
The original phase I C. burnetii, FastProtein Blue extract (bbAg), detergent 
extract (detAg), final pellet, and formalin-killed C. burnetii (WCV-I) were compared by 
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western-blot and silver stain; 8µg per well were loaded for each protein. The gel transfer 
was blocked for 1h in 10% milk then incubated for 1h with 1:400 mouse infection-
derived serum in 5% milk PBS-T and washed for 15 min with PBS-T.  A 1 h incubation 
with 1:10,000 goat anti-mouse IgG HRP in 5% milk PBS-T was followed by a 45 min 
wash.  
Experimental design. 1) Guinea pigs were infected via aerosol with 105 phase I 
C. burnetii Nine Mile (RSA493) in PBS using a chamber expressly designed to deliver 
droplet nuclei to the alveolar spaces (College of Engineering Shops, University of 
Wisconsin, Madison, WI) (108, 176),(137). Negative control animals were given PBS 
alone. Four animals per time point were euthanized at 7, 14, and 28 days post-infection. 
Blood, inguinal and axillary lymph nodes and spleen were collected aseptically for use 
in lymphoproliferation and cytokine assays. A second group of animals was challenged 
with a potentially lethal dose of 106 organisms and euthanized at 28 days post infection 
for evaluation of lymphoproliferative response. 
2) Three guinea pigs per group were given 106 C. burnetii of Nine Mile RSA 
493, P Q173, G Q212, or Dugway 5J108-111 isolates and euthanized at 14 days post 
infection for assessment of differential lymphoproliferative responses. 
2) Guinea pigs were given subcutaneous injections of 0.2μg, 2μg, or 20μg 
formalin-killed phase I (WCV-I) or phase II (WCV-II) Nine Mile C. burnetii in 
incomplete Freund’s adjuvant twice, with a two week interval between vaccinations and 
between the final vaccination and infection with 2x106 phase I C. burnetii. Temperature 
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and weight measurements were taken daily; temperatures ≥39.5°C were considered 
fever. Animals were necropsied 14 days post infection, and the spleen was weighed. 
3) Guinea pigs were given subcutaneous injections of 20μg WCV-I or WCV-II in 
incomplete Freund’s adjuvant twice, with a two week interval between vaccinations. 
Four weeks after the final vaccination, blood, lymph nodes, and spleen were aseptically 
collected at necropsy for use in lymphoproliferation and cytokine assays. 
Isolation and preparation of lymphocytes. Single-cell suspensions were 
prepared from the aseptically collected spleen and lymph nodes by gently homogenizing 
the tissues in sterile glass homogenizers with tissue culture medium [RPMI 1640 
supplemented with HEPES buffer, 10% fetal bovine serum, 2-mercaptoentanol (10 μm), 
L-glutamine (2 μm), penicillin (100 U/ml), and streptomycin (100 μg/ml)] and passing 
them through wire filters (109). Cells were spun down and washed in media twice before 
final suspension. Blood collected at necropsy was diluted in Hank’s PBS + 5mM EDTA 
and incubated at room temperature for 1 h. The suspension was then layered over 
Histopaque 1.107 (Sigma Chemicals, St. Louis, MO) and centrifuged at 250 x g for 40 
min at room temperature as previously described (109, 123). The buffy coat was 
removed and peripheral blood mononuclear cells (PBMC) were washed 3x with Hank’s 
PBS. After the final wash, cells were resuspended in tissue culture media. The viability 
of the lymphocyte suspensions was determined by trypan blue exclusion. 
Lymphoproliferation assay. Lymphocytes harvested from blood, lymph nodes, 
and spleens of control, infected, and vaccinated guinea pigs were analyzed for their 
ability to proliferate in vitro according to an established procedure (28, 109, 123) in 
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response to concanavalin A (ConA), phytohemagglutinin-P (PHA), pokeweed mitogen 
(PWM) (Sigma Chemicals, St. Louis, MO), or WCV-I. Lymphocytes were seeded into 
96-well plates at a concentration of 2x105 per well for splenocytes and PBMC and at 
4x105 per well for lymph node-derived cells. Triplicate cultures were stimulated with the 
mitogens or antigen at a concentration of 10 μg/ml and incubated for 4 days at 37°C and 
5% CO2. [3H]-thymidine was added for the last 6 hours of culture, and the contents of 
each well were then harvested onto glass fiber filters and quantitated using a liquid 
scintillation counter (LS 8000; Beckman, Irvine, CA). The stimulation index was 
determined by dividing the counts per minute of [3H]-thymidine taken up by stimulated 
cells by the counts per minute of unstimulated cells from the same source. 
 Cell stimulation. Splenocytes were cultured in 24-well tissue culture plates at 
5x105 cells per well and incubated in either medium alone or medium plus 10 μg/ml 
WCV-I. Cells were collected at 0, 3, 6, 12, and 18 h for RNA isolation and analysis by 
quantitative PCR. 
Total RNA isolation and quantitative PCR. Real-time PCR was performed on 
splenocyte cultures to determine mRNA levels for IFN-γ, TNF-α, TGF-β, RANTES, IL-
1β, IL-8, IL-10, IL-12p40, and HPRT (hypoxanthine phosphoribosyl-transferase). Total 
RNA was isolated from splenocyte cultures at 1, 3, 6, 12, and 18 h using RNeasy 
columns (Qiagen, Valencia, CA) treated with RNase-free DNase to remove 
contaminating DNA.  Reverse transcription with Taqman Reverse Transcription 
Reagents and real-time PCR using SYBR Green I double-stranded DNA binding dye 
(Applied Biosystems, Foster City, CA) were used according to established procedures 
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(89). The real-time primer sequences used have been previously reported (2, 89, 148, 
149)and are given in Table 4.1. Fold induction of mRNA was determined from the 
threshold cycle values normalized for HPRT expression and then normalized to the 
value derived from unstimulated cells from the same source. Ex vivo samples were 
normalized to HPRT and the mean value derived from normal, healthy control animals. 
Statistical analysis. Results were expressed as the means +/- the standard error 
and were compared using one- and two-way ANOVAs, Tukey’s multiple comparison, 
and student’s t-tests. Differences were considered significant at p<0.05. 
 
RESULTS 
The guinea pig immune response to infection and vaccination was evaluated by 
determining lymphoproliferative responses to mitogenic and antigenic stimulation and 
examining the production of mRNA for eight cytokines depicting both pro- and anti-
inflammatory responses.  
 Stimulation with C. burnetii antigen enhanced cytokine mRNA production. 
To establish times of peak inducible cytokine mRNA expression in response to C. 
burnetii antigens, splenocytes from normal, control guinea pigs were stimulated with 
WCV-I. WCV-I did induce expression of cytokine message RNA in normal cells 
compared to unstimulated controls, although at 10μg/ml WCV-I was found to be only a 
weak stimulating antigen. Hours of peak cytokine mRNA induction in response to 
antigenic stimulation were as follows: IFN-γ, 12-18 h; TNF-α, 6 h (p<0.05); IL-1β, 6 h; 
IL-8, 6 h; IL-10, 12 h; and IL-12p40, 6-18 h. C. burnetii antigenic stimulation did not 
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increase mRNA production in the time range evaluated for TGF-β or RANTES (Fig. 
4.1). 
 Increased pro-inflammatory cytokine mRNA with C. burnetii infection ex 
vivo and post-stimulation. Once it was determined that WCV-I stimulation of cells 
from healthy donors induced cytokine expression, induction of mRNA from ex vivo 
splenocytes following 7, 14, or 28 days of infection were evaluated and normalized to 
values of non-infected control animals with differences noted for several cytokines 
through the course of infection. A statistically significant increase  in IFN-γ at 28 days 
p.i. was identified when compared to samples from non-infected controls and infected 
animals at 7 and 14 days p.i. (p<0.01). A significant decrease was noted at 14 days p.i. in 
TNF-α compared to non-infected controls and infected animals at 7 and 28 days p.i. 
(p<0.01). IL-10 mRNA expression was reduced at 7 days p.i. (p<0.05). Minor, though 
statistically significant, decreases in expression of TGF-β were present at 7 and 28 days 
p.i (p<0.05). Changes in mRNA expression of IL-12p40 were also dependent upon 
infection duration (p<0.05), with significantly reduced levels at 7 days p.i. rising to 
levels above controls by 28 days p.i. No significant change in ex vivo mRNA expression 
was recognized for RANTES, IL-1β, or IL-8 (Fig. 4.2). 
Response to recall antigen provided another means to evaluate the immune 
response to C. burnetii infection. IFN-γ mRNA fold induction was increased at 7, 14, 
and 28 days p.i, at 12 and 18 h after stimulation with C. burnetii antigen, with peak 
induction occurring at 14 days p.i.  IL-12p40 was significantly induced at 28 days post 
infection and 6 h post stimulation (p<0.05). IL-10 induction was also increased at 28 
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days p.i. at 6 (p<0.05), 12, and 18 h post stimulation. Splenocytes from 28 day p.i. 
animals displayed increased TNF-α induction at 3 h post stimulation, whereas those 
from 7 and 14 days p.i. had a slight reduction. An approximately 2-fold reduction in IL-
1β was noted at 12 and 18 h post antigenic stimulation in all infected animals when 
compared to controls (Fig. 4.3). There was no detectable induction of TGF-β, RANTES, 
or IL-8 at any point post infection, as with ex vivo samples. It should be noted that 
significances in fold change were as compared to stimulated, non-infected controls. 
Suppression of lymphoproliferation following infection with C. burnetii.  The 
lack of general cytokine induction after infection with C. burnetii, especially at 14 days 
p.i., was unexpected given the clinical development of fever and pulmonary pathology. 
An early report of C. burnetii infection in monkeys and guinea pigs (75) suggested that 
infection induces immunosuppression. Therefore, the general function of lymphocyte 
activity was evaluated following infection.  
Non-specific suppression of mitogen-stimulated lymphoproliferation was noted 
in infected guinea pig lymph node cells (Fig. 4.4), splenocytes, and PBMC at 14 and 28 
days p.i. when compared to non-infected controls (p<0.05). No such suppression was 
seen at 7 days p.i. 
Differential protectivity of phase I and phase II vaccination. Animals, 
including guinea pigs, as well as humans, develop long-lived protective immunity after 
vaccination with whole killed phase I C. burnetii. In contrast, whole killed phase II C. 
burnetii vaccination results in a strong immune response with limited or inapparent 
protection from challenge by virulent organisms. This distinction in the ability to 
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engender protection was noted early in C. burnetii research (120), but the molecular 
correlates that distinguish these two vaccination responses have not been characterized. 
Before analysis of immunologic responses to vaccination, protective efficacies of 
vaccine preparations from phase I and phase II C. burnetii organisms were determined. 
Guinea pigs vaccinated with 0.2μg WCV-I and WCV-II developed fever similar to non-
vaccinated controls in response to challenge with 106 virulent C. burnetii, but those 
receiving WCV-I were protected against death while 3/3 non-vaccinated and 2/3 WCV-
II-vaccinated animals succumbed to infection. Guinea pigs vaccinated with 2 and 20μg 
WCV-II had fever of a lesser degree and shorter duration than non-vaccinated controls 
with no fatalities. Administration of 2 or 20μg WCV-I provided complete protection; no 
guinea pigs vaccinated with 2 or 20μg WCV-I exhibited clinical signs of illness (Fig. 
4.5). Peak splenomegaly in response to high-dose C. burnetii infection occurs at 14 days 
p.i. (137). Because non-vaccinated control animals died before this point, an adequate 
comparison of spleen weights between vaccinated and control animals could not be 
performed. However, spleen weight and spleen/body weight ratios decreased with 
increasing doses of vaccine, both WCV-I and WCV-II, and animals receiving 20μg 
WCV-I had no discernible splenomegaly (data not shown). 
Increased expression of pro-inflammatory cytokine IFN-γ with protective 
vaccination. C. burnetii infection appeared to drive a Th1-dominant immune response, 
as described above, but it was unknown what similarities infection-derived immunity 
would share with vaccination-induced immunity. Splenocytes from vaccinated, non-
infected guinea pigs were evaluated for their production of cytokine mRNA ex vivo and 
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upon stimulation with WCV-I to assess differences resulting from fully-protective 
WCV-I and partially-protective WCV-II vaccination. A minor but significant reduction 
of TNF-α (p<0.05) in ex vivo splenocytes from WCV-II-vaccinated animals was noted 
when compared to controls. There was also a non-significant ~2-fold reduction in IL-1β. 
No significant induction or reduction of IFN-γ, TGF-β, RANTES, IL-8, or IL-10 were 
evident post vaccination in ex vivo samples. 
Increased IFN-γ induction was noted at 12 and 18 h post antigenic stimulation in 
splenocytes from WCV-I-vaccinated guinea pigs when compared to WCV-II-vaccinated 
animals and controls. TNF-α was increased in samples from WCV-I animals at 3 
(p<0.05) and 6 h post stimulation. WCV-I vaccination induced IL-12p40 at 6 and 12 h 
post stimulation. Vaccination with WCV-I and WCV-II caused slight increases in IL-8 
induction at 3 and 6 h post stimulation and in IL-10 at 6 (p<0.05) and 12 h, with IL-10 
mRNA production greater in samples from WCV-II vaccinated animals (Fig. 4.6). 
Vaccination had no effect on TGF-β, RANTES, IL-1β. 
Protective vaccination stimulates lymphoproliferation. Increased 
blastogenesis in response to mitogenic and C. burnetii antigenic stimulation was noted in 
splenocytes, lymph node-derived lymphocytes (Fig.4.7), and PBMC from vaccinated 
guinea pigs, with WCV-I eliciting stronger mean responses than WCV-II. The antigen-
specific enhancement of the lymphoproliferative response was significantly greater in 
WCV-I vaccinated animals (p<0.05). In order to illustrate that differences in 
lymphoproliferative responses were not due to potential differences in the ability to 
respond to fixed antigen, additional soluble antigen preparations were also evaluated. As 
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seen in both western-blot and silver stain (Fig. 4.8), the majority of the proteins in the 
whole bacteria (Lane 1) were also present in the FastProtein Blue extract (Lane 2) and 
the detergent extract mixture (Lane 3). Only a few strongly antigenic proteins remained 
in the unsoluble fraction (Lane 4). No significant differences were noted in fixed whole 
cell vs. soluble antigen stimulation of lymphoproliferation. 
C. burnetii virulence is associated with suppression of lymphoproliferation. 
To test whether suppression of lymphocyte proliferation was unique to infection with 
Nine Mile isolate, we compared lymphocytes from animals infected with isolates with 
distinct virulence phenotypes, as shown in our previous study (manuscript in 
preparation). Nine Mile RSA493 caused fever and severe atypical pneumonia while 
lesser disease was seen with P Q173 and G Q212, and no evidence of clinical illness was 
noted following Dugway 5J108-111 infection. Lymphoproliferation of PHA-stimulated 
lymph node cells was significantly suppressed in cultures from guinea pigs infected with 
RSA493 (p<0.01), Q173 (p<0.01), and Q212 (p<0.05) when compared to non-infected 
controls and those challenged with 5J108-111 (Fig. 4.9), adding differences in 
immunosuppressive response to infection to differences in clinical disease presentation 
between isolates. 
 
DISCUSSION 
Infection with C. burnetii leads to a range of immune responses in the host 
dependent on the stage of infection. In the guinea pig model, infection with 105 C. 
burnetii organisms via aerosol results in fever starting around day 6 p.i and lasting 
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approximately 7 days (137). The time-points evaluated here, 7, 14, and 28days p.i., were 
intended to allow evaluation of the host immune response in early, late, and convalescent 
stages of acute infection.  
IFN-γ activates macrophages and enhances their ability to destroy ingested 
microorganisms. IFN-γ is produced by Th1 cells in response to stimulation by IL-12, 
which is produced by activated macrophages, and IL-2, which is also produced by Th1 
cells, creating a strong stimulatory loop in response to infection. IFN-γ also enhances 
NK cell activity and expression of TNF-α receptors. Reactive oxygen and nitrogen 
intermediates produced in response to IFN-γ stimulation have been shown to inhibit C. 
burnetii replication and are likely to play a role in the host control of infection (16, 60), 
though the effects of IFN-γ may not be exclusively due to nitric oxide production since 
IFN-γ also controlled the infection in macrophages derived from inducible nitric oxide 
synthase knockout mice (190). It has also been proposed that IFN-γ stimulates the killing 
of C. burnetii by causing phagosome maturation and alkalinization (43) and promotes 
apoptosis of infected monocytes by  activation of caspase-3, which is dependent on the 
expression of membrane TNF in cell culture systems (33), although these reports have 
not been substantiated by other studies. Here we show that IFN-γ mRNA was primarily 
induced at 12 and 18 h post stimulation with WCV-I in splenocytes from both infected 
and non-infected guinea pigs. Though it was expected that an increase in IFN-γ would be 
seen in response to active infection due to its established role in the inflammatory 
response, ex vivo expression was only noted during the convalescent stage at 28 days p.i. 
Induction following antigenic stimulation, though evident at both 14 and 28 days p.i, 
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was slightly higher at the 14 day time-point. These increases in IFN-γ during late 
infection and early convalescence suggest a role for IFN-γ in the control of C. burnetii 
infection in the guinea pig model. Splenocytes from animals receiving phase I 
vaccination were more capable of IFN-γ mRNA induction after antigenic stimulation 
than those of phase II vaccinees and normal guinea pigs. It has been demonstrated that 
stimulation of human PBMC with WCV-II causes a greater IFN-γ response than WCV-I, 
and the presence of phase I LPS actually has a down-regulatory action on IFN-γ 
production, which is offset by the addition of IL-2 to the cultures (65). It has also been 
shown in mice that the non-specific anti-viral immunity induced by vaccination with C. 
burnetii is dependent on IFN-γ, since signaling through the IFN-γ receptor is essential 
for the production of nitric oxide, indoleamine 2,3-dioxygenase, 2’-5’-oligoadenylate 
synthetase, and protein kinase (136). An increase in IFN-γ has been noted in patients 
with post-Q fever fatigue syndrome (122) but is not commonly reported in Q fever 
endocarditis patients. Q fever patients deficient in specific T cell activity may be unable 
to contain the organism in phagocytes and granulomas (78), as in TLR4-/- mice where 
impaired formation of granulomas has been associated with decreased IFN-γ and TNF-α 
production (57). Other studies have shown that TLR2, not TLR4, is important for 
recognizing C. burnetii and limiting its growth, where macrophages lacking TLR2 but 
not TLR4 produce less TNF-α and IL-12 when infected with the organism (189).. 
TNF-α is a major immune response-modifying cytokine produced principally by 
activated macrophages and is involved in inflammation (including fever) and cell death 
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and may induce IL-1 release. C. burnetii antigen caused increased induction of TNF-α 
mRNA in splenocytes from normal, healthy animals. Interestingly, TNF-α mRNA levels 
were decreased in ex vivo cells from infected guinea pigs when clinical illness was 
resolving, and no significant change was noted upon stimulation of splenocytes with 
recall antigen. It is possible that the window of TNF-α induction was missed due to 
experimental design; daily evaluation during the infectious process might reveal the 
expected rise in TNF-α. Increases in TNF-α secretion have been shown from ex vivo 
PBMC of patients with acute Q fever, though levels were reportedly higher in samples 
from patients with acute hepatitis than those with pneumonia, but C. burnetii-stimulated 
cytokine production was no different than controls (58). Another study showed that both 
TNF-α and TNF receptor II, a cytokine antagonist, were increased in acute Q fever and 
Q fever endocarditis (23). Overproduction of TNF-α has commonly been reported in 
association with chronic Q fever endocarditis (26, 58). It has been proposed that 
differences in TNF-α induction might play a role in the pathobiology of Q fever, 
supported by the findings that the most effective inducers in a TNF-bioassay of 
peritoneal macrophages from naïve mice were the LPS and whole cell antigens of 
Priscilla (Q177), Scurry (Q217), Nine Mile (RSA493), Luga (Q216), and Henzerling 
(RSA331), in that order, whereas by ELISA the best inducers were the LPS of Luga, 
Henzerling, Nine Mile, Priscilla, then Scurry (79). Neither infection with C. burnetii 
Luga strain nor vaccination with whole killed cells lead to an increase in TNF in the 
serum of mice, though stimulation by intravenous injection of WCV-I post-infection 
caused marked TNF production (166). In our study, vaccination of guinea pigs with 
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WCV-I provoked an increase in TNF-α mRNA induction compared to WCV-II and non-
vaccinated controls. Blood cell cultures from healthy humans incubated with WCV-I 
from Nine Mile and Priscilla strains of C. burnetii induced significantly higher levels of 
TNF-α secretion than WCV-II of the same isolates. Those experiments demonstrated 
that the higher the LPS content, the more pronounced the induction of TNF-α, as well as 
IL-6 and IL-8, secretion (81). 
IL-1 is a major pro-inflammatory cytokine secreted by macrophages in response 
to phagocytosis of foreign particles or T cell contact with macrophages that activates T 
cells in response to antigen and induces T-cell expression of IFN-γ. It was anticipated 
that an increase in IL-β mRNA would be seen during early infection since IL-1 is known 
to cause fever by stimulating the release of prostaglandins and stimulates the release of 
and is chemotactic for neutrophils, which have been found in abundance in C. burnetii 
infected tissues at 7 days p.i. (137).  Interestingly, IL-1β does not appear to be increased 
during the febrile stage of infection in the guinea pig aerosol-challenge model, and 
mRNA levels were in fact lower in infected animals compared to non-infected controls 
in ex vivo and stimulated splenocytes. It would be desirable to test for IL-1 receptor 
agonist (IL-1RA) in the guinea pig model since it has previously been found that IL-
1RA was significantly increased in plasma from patients with acute Q fever (23). On the 
contrary, IL-1β production by PBMC from patients with chronic Q fever endocarditis is 
greatly increased (26). Normal human blood cell cultures incubated with antigens from 
both the acute disease-associated strain Nine Mile and the chronic disease-associated 
  
63
 
strain Priscilla showed no increase in IL-1β secretion (81), and similar results were 
found in cultured splenocytes in the guinea pig model. 
IL-12 is a pro-inflammatory cytokine produced by activated macrophages that 
acts on Th1 cells to enhance the secretion of IFN-γ. IL-12p40 mRNA induction in 
guinea pig splenocytes in response to C. burnetii antigenic stimulation occurred between 
6 and 18 h post-stimulation. Ex vivo samples exhibited a significant reduction at 7 days 
p.i., gradually returning to control levels by 28 days p.i., at which time splenocytes 
exposed to antigen had a significant increase in IL-12p40. Vaccination with WCV-I also 
lead to an increase in IL-12p40 mRNA induction compared to WCV-II administration or 
non-vaccination. Patients with uncomplicated acute Q fever and Q fever valvulopathy 
have exhibited an increased release of IL-12 from unstimulated PBMC, but the level of 
cytokine production was not affected by the amount of time between disease onset and 
cytokine analysis (58).  
IL-10 is produced by activated macrophages and Th2 cells (and Th1 cells in 
humans) and directly inhibits cytokine synthesis by macrophages, reducing the 
production of IL-12 and TNF-α. The reduction in IL-12 production in turn results in a 
decrease in Th1 derived IFN-γ. Overproduction of TNF can stimulate monocyte 
production of IL-10, causing a negative feedback loop. IL-10 can also stimulate the 
production of IL-1RA, leading to a decrease in IL-1. IL-10 mRNA was reduced in ex 
vivo guinea pig splenocytes after infection with C. burnetii, with the greatest degree of 
reduction corresponding to the early stage of febrile illness. However, IL-10 was 
significantly induced in 28 day p.i. samples after antigenic stimulation, as would be 
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expected to control the host inflammatory response caused by active infection. A slightly 
greater induction of IL-10 was noted in guinea pigs after vaccination with WCV-II at 12 
hours post-stimulation when compared with WCV-I, indicating a stronger Th1 response 
to protective vaccination and associating a possible Th2 skew with phase II vaccination. 
The overproduction of IL-10 has been associated with chronic Q fever endocarditis and 
fatigue syndrome (42, 122) due to defective phagosome maturation and impaired C. 
burnetii killing (44) and is specifically associated with the occurrence of relapses (25). 
Increased IL-10 release has also been noted in acute Q fever hepatitis patients (58).  
Very few changes in TGF-β, RANTES, and IL-8 mRNA were observed in 
infected or vaccinated guinea pigs. TGF-β is produced by activated macrophages and T 
cells and inhibits IL-1 and IFN-γ production. TGF-β is also known to inhibit T cell 
proliferation, so it is somewhat interesting that TGF-β mRNA levels were not increased 
at times when suppression of lymphoproliferation was noted with the [3H]-thymidine 
assay. Monocytes from patients with Q fever endocarditis have been shown to release 
TGF-β (25), and levels are increased in the serum of post-Q fever fatigue syndrome 
patients (122). RANTES is a β-chemokine produced by circulating T cells and, as its 
name implies (Regulated upon Activation, Normal, T Expressed and Secreted), is 
reduced when T cells are activated. It has been suggested that RANTES plays a role in 
regulating the inflammatory response to LPS in the guinea pig by altering macrophage 
production of pro-inflammatory cytokines (148), but no significant changes were noted 
after C. burnetii infection or vaccination. RANTES has been shown to increase 
phagocytosis of virulent C. burnetii by THP-1 cells, preventing C. burnetii replication 
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but not elimination (24).  IL-8 is produced by macrophages and is chemotactic for 
neutrophils and certain T cells. Slight increases in IL-8 were seen at 6 h post-stimulation 
in normal cells and in those acquired from animals vaccinated with WCV-I and WCV-II. 
Secretion of IL-8 has been noted in normal blood cell cultures stimulated with Nine Mile 
and Priscilla antigens and was independent of the phase of antigen used (81).  
The formalin-killed, whole-cell C. burnetii vaccine is known to be highly 
immunogenic and protective in both humans and animals (1, 179). The immune response 
seen post-vaccination in humans has been evaluated through cell mediated immunity, 
known to be a factor in resistance to C. burnetii infection (107), and antibody response 
(7, 185). Formalin-killed phase I Coxiella have been shown to be 100-300 times more 
protective than phase II organisms (120). Comparison of these two immunizing 
materials provides an important approach to examining protective immunity. In this 
study, we showed that as little as 2µg of WCV-I conferred complete protection against 
fever and death in the guinea pig aerosol-challenge model in response to infection with a 
potentially lethal dose of C. burnetii. WCV-II vaccination conferred only partial 
protection at higher doses, preventing death and reducing but not eliminating the febrile 
response. As discussed above, increased induction of certain cytokines such as IFN-γ, 
TNF-α, and IL-12p40 after vaccination with WCV-I, in conjunction with the increase in 
IL-10 seen with WCV-II vaccination, support the necessity of a Th-1 dominant immune 
response in protective vaccination. 
In our study, guinea pig splenocytes, PBMC, and lymph node cells exhibited 
marked lymphocyte hyporesponsiveness at 14 and 28 days p.i. but not during clinically 
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apparent infection at 7 days p.i. This suppression of lymphoproliferation may be due to 
corresponding increases in IFN-γ, which can have immunosuppressive as well as 
immunostimulatory effects. Suppression of blastogenesis of PBMC from cynomolgus 
macaques in the presence of PHA has been shown to occur between 14 and 28 days post 
infection with C. burnetii Henzerling at which times lymphocyte counts were within 
normal limits and clinical signs of illness had abated; similar results were seen in guinea 
pigs during early convalescence. Cynomolgus lymphocytes were again responsive on 
day 35 p.i. when cultured with WCV-I or WCV-II (75). PBMC from patients that have 
recovered from acute Q fever and those from patients with active Q fever hepatitis 
exhibit a strong proliferative response when cultured with C. burnetii antigens (78). Q 
fever endocarditis patients have been shown to have an antigen-specific lymphocyte 
unresponsiveness, mediated in part by adherent suppressor cells that work through the 
production of prostaglandin E2 (PGE2) (77, 78).  It has been demonstrated that C. 
burnetii contains an immune suppressive complex (ISC) attached to the cell matrix by 
disulfide bonds (171). This ISC was expressed by phase I but not phase II organisms and 
lead to mitogen hyporesponsiveness and antigen-specific down-regulation of splenic and 
nodal lymphocytes from C57BL/10 mice infected with phase I C. burnetii (29). In that 
model, vaccination also induced dose-dependent lymphocyte hyporesponsiveness to 
phytomitogens. On the other hand, lymphocytes from humans vaccinated with Q-Vax or 
other phase I vaccines exhibit a mitogenic response to C. burnetii antigens (65, 70), and 
PBMC from guinea pigs vaccinated with a killed phase I C. burnetii vaccine had 
increased stimulation indices when stimulated with PHA (74). An increase in 
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lymphoproliferation in response to mitogenic and C. burnetii antigenic stimulation in 
vaccinated guinea pigs, particularly after vaccination with WCV-I, was also 
demonstrated in our study. Previously, no immunosuppression was seen in mice injected 
with phase I strains isolated from heart valves of individuals with chronic Q fever 
endocarditis, KAV and PAV (171). However, we have shown here that 
lymphoproliferation of PHA-stimulated lymph node cells was significantly suppressed in 
cultures from guinea pigs infected with two endocarditis-derived isolates, P Q173 and G 
Q212, and the acute disease-associated Nine Mile RSA493, but not from those 
challenged with Dugway 5J108-111, elucidating yet another facet of the complex 
interactions between C. burnetii isolates of differing genetic compositions and the host 
immune response and showing similar suppression of lymphoproliferation in isolates 
inducing different degrees and types of clinical illness in the guinea pig model. 
We evaluated the guinea pig immune response to infection via aerosol and 
vaccination with protective and partially protective vaccine preparations. Cytokine 
analyses and lymphoproliferative responses indicate a role for Th1 dominant cell-
mediated immunity in infection and protective vaccination. Few immunologic tools have 
been developed for analysis of the guinea pig immune response, but with the recent 
completion of the guinea pig genome sequence analysis, it is anticipated that primers for 
more key cytokines will soon be available. This will allow further much-needed analysis 
of the immune response associated with infection and required for effective vaccination. 
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V. SUMMARY AND CONCLUSIONS 
  
There was a great need in the Coxiella burnetii research field for a fully-
characterized animal model system that could adequately mimic both the common route 
of infection and major manifestations of clinical illness of human acute Q fever. The 
aerosol-challenged guinea pig model presented here meets these criteria and evaluation 
of this model has lead to further appreciation of the host response to C. burnetii 
infection.  The objectives of this dissertation were to develop and characterize a guinea 
pig model infected via aerosol with C. burnetii, assessing clinical, pathologic, and 
immunologic responses to infection. This model was then used to determine the 
consequences of infection with multiple C. burnetii isolates representing four separate 
genomic groups and to compare the protective efficacies of vaccination with killed phase 
I and phase II organisms. 
The dose-responsive nature of infection with C. burnetii in the guinea pig 
aerosol-challenge model corresponded with what had been previously, albeit to a lesser 
extent, characterized in other models, including humans (13, 83, 116), and spanned 
disease ranging from largely subclinical illness with minor febrile response to lethal 
pneumonia. The development of exceptionally high fever (40-40.5°C;104-105ºF) in the 
guinea pig model was reliably reproducible and one of the hallmarks of human infection 
with C. burnetii. Histopathologic evaluation during active infection in guinea pigs 
receiving a large number of C. burnetii Nine Mile RSA493 organisms revealed 
coalescing panleukocytic, bronchointerstitial pneumonia with extensive bronchial and 
alveolar exudates that resolved to multifocal, lymphohistiocytic, interstitial pneumonia 
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with granuloma formation during convalescence. These findings are compatible with 
those seen when human cases of acute Q fever develop pneumonic complications (98, 
100, 118). The development of pneumonia proved to be one of the outcomes of infection 
with not only the genogroup I isolates Nine Mile RSA493, African RSA334 and Ohio 
314 RSA270, but also to lesser degrees with other isolates more commonly associated 
with chronic disease symptomology, including, in descending order of severity of 
pneumonic disease, group V isolates S Q217 and G Q212 and group IV isolates P Q173 
and MSU Goat (Priscilla) Q177. No clinically significant abnormalities were noted in 
guinea pigs infected with any dose of the group VI isolate 5J108-111 as was expected 
since isolates in this group have generally been considered avirulent, though infectious 
(158, 159). A large amount of lipid accumulation was noted in the livers of severely ill 
animals necropsied during early infection, which, though not a common manifestation of 
human Q fever, has been previously reported in guinea pigs infected IP (15). Infection 
with group IV isolates, particularly P Q173, was associated with a notably increased 
incidence and severity of granulomatous hepatitis, similar to that seen in human acute Q 
fever hepatitis cases exhibiting primarily granulomatous inflammation, though the 
“doughnut” granulomas associated with that condition were not noted in any infected 
guinea pigs. In general, where pneumonia was more advanced with I, V, then IV 
infection, hepatitis was more severe in IV, V, then I-infected animals, indicating that 
although route of infection is likely to play some role in the manifestation of disease as 
has been previously demonstrated (83, 102), the genetic composition of the infecting 
bacteria is also a major, and possibly more important, contributing factor.  
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In addition to unique sequence differences between genomic groups that may 
contribute to differences in disease manifestation, host factors such as 
immunocompetence/suppression are also likely to play a role, and, indeed, host 
immunogenetic differences have been noted in patients with acute Q fever, Q fever 
endocarditis, and post-Q fever fatigue syndrome (53). Severe combined 
immunodeficient mice, lacking both B and T cell responses, are highly susceptible to 
infection with C. burnetii and studies have suggested that innate immunity cannot 
control replication of the bacteria and acquired immunity is essential for mice to survive 
infection (3, 4).  The cell-mediated immune response is considered an essential 
component for controlling C. burnetii infection (10), and experiments in knock-out mice 
have shown that T cells are crucial for the clearance of both phase I and phase II C. 
burnetii (M Andoh, manuscript in preparation). These findings concur with evidence that 
infection with human immunodeficiency virus is a risk factor for the development of 
chronic Q fever endocarditis (19, 90). It was interesting to note that similar suppression 
of lymphoproliferation was seen after infection with isolates producing disparate 
diseases (RSA493, Q173, and Q212) while no suppression was noted in an avirulent 
isolate (5J108-111). The suppression of lymphoproliferative responses seen after active 
infection with isolates from three separate genomic groups (I, IV, and V) in the guinea 
pig model has also been reported following both acute and chronic human infections (75, 
171) and was found to be due to prostaglandin E2 production by stimulated monocytes 
(77).This suppression following acute infection may be a contributing factor in latent 
infection, which could in turn develop into chronic disease, particularly in individuals 
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with prior valvulopathies or immunosuppressive events such as chemotherapy. Infection 
of guinea pigs with C. burnetii via aerosol lead to an assortment of modifications of the 
host immune response dependent on the stage of infection. Increased induction of 
mRNA was noted in Th1 cytokines such as IFN-γ and IL-12p40 in response to infection 
and re-stimulation with C. burnetii, primarily in animals sampled at 28 days p.i., though 
IL-12p40 was significantly reduced in ex vivo samples during early infection. The 
mRNA production was also increased in the Th2 cytokine IL-10 at 28 days p.i. The other 
cytokines monitored were either slightly decreased (IL-1β) or showed little to no change 
(TGF-β, RANTES, IL-8). A major limitation of the assessment of cytokine response to 
infection was the amount of time between sample collections, potentially leading to 
missing the window of expression of TNF-α and other cytokines. 
Vaccination with phase I antigens derived from two separate genomic groups 
showed complete heterologous protection against lethal challenge. Comparison of phase 
I (WCV-I) and phase II (WCV-II) antigenic preparations of RSA493, however, revealed 
only partial protection in response to infection (protection against death but not fever) 
after WCV-II administration as opposed to the complete protection offered by WCV-I, 
confirming the results of a similar early study (120). WCV-I , and to a lesser extent 
WCV-II, administration stimulated an increase in lymphoproliferation in a [3H]-
thymidine uptake assay upon stimulation with the mitogens ConA, PHA, and PWM as 
well as three different preparations of phase I C. burnetii antigen. This increased 
blastogenic response after vaccination with phase I. C. burnetii has also been noted in 
humans (65, 74, 179). Th1 cytokine response to vaccination was clearer than that of 
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infection with increased production of IFN-γ, TNF-α, IL-1β, and IL-12p40 mRNA after 
antigenic stimulation associated with WCV-I vaccination when compared to WCV-II 
vaccination, and an increase in IL-10 in samples from WCV-II vaccinated animals. 
Overall, cells from guinea pigs vaccinated with WCV-II did not respond to recall antigen 
with the same efficiency as cells from animals vaccinated with WCV-I. It would be 
attractive to infer that a Th1 immune response is required for protective vaccination, 
while the WCV-II vaccine is less protective due to a skew towards a Th2 response. 
However, it is more likely that the difference is simply a stronger vs. less strong Th1 
response to WCV-I vs. WCV-II vaccination. 
Clinical signs, pathologic changes, and immunologic responses noted in guinea 
pigs infected via aerosol are comparable to those seen in human acute Q fever, making 
this an accurate and valuable animal model of human disease. This physiologically 
relevant model will be important for testing prospective preventative and therapeutic 
agents, evaluating potential improved diagnostic tests, and further exploration of the 
general pathogenesis of C. burnetii infection, including a more detailed analysis of host 
immune response to infection and protective vaccination. Key findings in the series of 
experiments presented here were: 1) the dose-responsive nature of C. burnetii infection, 
including in depth examination of the associated pathologic changes; 2) genetic 
differences among C. burnetii isolates are responsible for variations in clinical disease 
presentation, and phylogenetic groupings may be used to anticipate the course of 
infection; 3) vaccination with whole killed cells from an isolate of one genetic group are 
protective against lethal infection with an isolate from another group; 4) vaccination 
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with whole killed cells from phase I, but not phase II, organisms is completely protective 
against lethal challenge; and 5) a stronger Th1 immune response is present in association 
with phase I vaccination when compared to phase II vaccination. 
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FIG. 2.1. Fever response and weight loss. Average daily temperatures (A) and weights 
(B) of control guinea pigs (S) and those infected with 2x106 C. burnetii (). 
Temperatures in excess of 39.5°C are considered fever. Weight loss and gain 
corresponded with the onset and resolution of fever. 
A 
B 
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FIG. 2.2. Percent survival after infection with 2x106 C. burnetii. Inoculation with 2x106 
C. burnetii resulted in mortality in 12/17 guinea pigs within the first 10 days of infection, 
with no deaths occurring thereafter. 
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FIG. 2.3. Transient splenomegaly in animals surviving 2x106 C. burnetii challenge. 
Spleen weights are the average of 3 guinea pigs infected with 2x106 C. burnetii 
euthanized at 7, 14, and 28 days post infection. Statistically significant splenomegaly 
was present at 14 days post infection (p<0.01). 
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FIG. 2.4. Q fever pneumonia. H&E stained lung tissues from guinea pigs infected with 
2x106 C. burnetii 7 and 28 days p.i. compared to PBS controls (A1-A3). Panleukocytic 
bronchointerstitial pneumonia with bronchial and alveolar exudates can be seen at 7 days 
p.i. (B1-B3); arrows indicate BALT. Granulomatous pneumonia was present 28 days p.i. 
(C1-C3); arrows indicate pulmonary granulomas. No significant pathologic change was 
noted in guinea pigs vaccinated prior to infection (D1-D3). 
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FIG. 2.5. Q fever hepatopathies and splenic changes. H&E stained liver and spleen 
sections showing (A) hepatic lipidosis, 7 days p.i.; (B) hepatic granuloma, 14 days p.i.; 
(C) disruption of normal splenic architecture, 14 days p.i.; and (D) splenic granulomas, 
14 days p.i., in guinea pigs infected with 2x106 C. burnetii. 
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FIG. 3.1. Fever response to infection with high dose C. burnetii isolates. Mean daily 
temperatures +/- SEM (n=3) of guinea pigs infected with 2x106 of each C. burnetii 
isolate. Temperatures ≥39.5°C are considered fever. Arrows indicate days on which 
death occurred in RSA493, RSA334, and RSA270 groups. 
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FIG. 3.2. Splenomegaly 14 days p.i. Spleen weights are the average of 3 guinea pigs per 
group infected with 2x106 C. burnetii euthanized at 14 days post infection. Statistically 
significant (p<0.05) splenomegaly was present in all guinea pigs receiving each C. 
burnetii isolate. Q173 and 5J108-111 were also statistically different from RSA493 
(p<0.01) and Q212 (p<0.05). *=p<0.05, **=p<0.01 compared to PBS controls. 
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A
 
B
 
 
FIG. 3.3. Q173 infection-associated hepatic granulomas. A) Pinpoint to 4mm, individual 
to coalescing, white foci in the liver of a guinea pig 28 days post infection with high-
dose phase I Q173 C. burnetii. B) 100x magnification of a single hepatic granuloma 
from the same guinea pig. 
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FIG. 3.4. Heterologous vaccination and challenge. Average daily temperatures of guinea 
pigs vaccinated with RSA 493 (dotted line), Q217 (dashed line), or adjuvant alone (solid 
line) and challenged with high dose RSA493 (♦) or Q217 (□). Temperatures ≥ 39.5°C 
were considered fever.  
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Fig. 4.1. Splenocyte cytokine response to C. burnetii antigen stimulation. Fold induction 
of mRNA derived from healthy control guinea pig splenocytes after stimulation with 
phase I C. burnetii antigen normalized to time zero. Y axis depicts hours post 
stimulation. *p<0.05; **p<0.01.
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Fig. 4.2. Ex vivo splenocyte cytokine levels following C. burnetii infection. Ex vivo fold 
induction of mRNA from splenocytes derived from guinea pigs aerosol-challenged with 
105 C. burnetii collected at 7, 14, and 28 days post infection compared to non-infected 
control animals. *p<0.05; **p<0.01. 
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Fig. 4.3. Peak cytokine response to C. burnetii antigen stimulation in splenocytes from 
infected guinea pigs. Cytokine mRNA fold induction in response to WCV-I stimulation 
of splenocytes from non-infected guinea pigs and those infected for 7, 14 and 28 days. 
Hours reported represent peak stimulation. *p<0.05; *p<0.01. 
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Fig. 4.4. Non-specific suppression of lymphoproliferation post infection. Non-specific 
suppression of lymphoproliferation of lymph node-derived cells with ConA mitogenic 
stimulation in response to 106 C. burnetii infection at 7, 14, and 28 days p.i. Stimulation 
index = counts per minute of [3H]-thymidine taken up by stimulated cells ÷ the counts 
per minute of unstimulated cells from the same source. *p<0.05; **p<0.01. 
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Fig. 4.5. WCV-I vs. WCV-II vaccination. Fever development post WCV-I and WCV-II 
vaccination. Guinea pigs receiving 2 or 20μg of WCV-I did not develop fever while 
those receiving WCV-II did. Fever was defined as temperatures ≥39.5°C. The non-
vaccinated animals’ data ends on day 9 due to death of all subjects in that group. 
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Fig. 4.6.  Peak cytokine response to C. burnetii antigen stimulation in splenocytes from 
vaccinated guinea pigs. Cytokine mRNA induction in response to WCV-I stimulation of 
spleen cells from WCV-I (diagonally lined) and WCV-II (horizontally lined) vaccinated 
and non-vaccinated (checkered) guinea pigs. *p<0.05; **p<0.01.
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Fig 4.7. WCV-I stimulation of lymphoproliferation. Enhanced lymphoproliferation of 
lymph node-derived cells with WCV-I vaccination in response to mitogenic (ConA, 
PHA, PWM) and antigenic (WCV-I, bbAg, detAg) stimulation. Stimulation index = 
counts per minute of [3H]-thymidine taken up by stimulated cells ÷ the counts per 
minute of unstimulated cells from the same source. *p<0.05. 
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Fig. 4.8. Western blot (A) and silver stain (B) analyses of C. burnetii proteins. M: Mark 
12 molecular weight marker; Lane 1: Phase I C. burnetii; Lane 2: FastProtein Blue 
extract; Lane 3: FastProtein Blue extract/detergent extract mixture; Lane 4: final pellet; 
Lane 5: WCV-I. 8µg of protein were loaded per well. 
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Fig 4.9. Non-specific suppression of lymphoproliferation following infection with 
virulent C. burnetii isolates. Lymphoproliferation of PHA-stimulated lymph node-
derived cells from guinea pigs infected for 14 days with various C. burnetii isolates.  
Stimulation index = counts per minute of [3H]-thymidine taken up by stimulated cells ÷ 
the counts per minute of unstimulated cells from the same source. *p<0.05; **p<0.01. 
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APPENDIX B 
 
TABLES 
 
 
TABLE 2.1. Response to infection with C. burnetii 
Infectious Fever/ Earliest Onset Average Fever Highest Death/ Seroconversion/ ELISA Titer 
Dose Total of Fever Duration (days) Temperature (°C) Total Total (range) 28days p.i.
PBS control 0/3 N/A N/A 39.3 0/3 0/3 0 
2x101 2/3 Day 14 1 39.6 0/3 3/3 100 
2x102 3/3 Day 14 1.67 39.9 0/3 3/3 400-800 
2x103 3/3 Day 10 2.67 39.9 0/3 3/3 1600-3200 
2x104 3/3 Day 6 4 40.6 0/3 3/3 3200-51200 
2x105 3/3 Day 6 6 40.9 0/3 3/3 51200-102400 
2x106 3/3 Day 5 5* 40.8 2/3 1/3* 25600 
2x106, vaccinated 0/3 N/A N/A 39.4 0/3 3/3 25600-102400 
*Number may be skewed due to death 
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TABLE 2.2. Severity* of histopathologic changes in selected tissues of guinea pigs 
infected with 2x106 C. burnetii 
 
 7 days p.i. 14 days p.i. 28 days p.i 
Lung 5 4 3 
Liver 4 3 3 
Spleen 2 3 2 
 
*Severity is based on the amount of architectural change, cellular infiltration, and the 
presence or absence of necrosis: 0, none; 1, mild; 2, mild to moderate; 3, moderate; 4, 
moderate to severe; 5, severe. Scores are the average of sections evaluated for 2 guinea 
pigs per time point.  
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TABLE 2.3. Histopathology* and immunohistochemistry# in selected tissues of guinea 
pigs infected with C. burnetii 
 
 Lung Liver Spleen 
 H* I# H* I# H* I# 
PBS Control 0 - 0 - 0 - 
2x101 1 - 0 - 0 + 
2x102 1 + 1 - 0 + 
2x103 2 + 1 + 1 ++ 
2x104 3 + 2 ++ 1 ++ 
2x105 3 ++ 2 ++ 1 +++ 
2x106 3 ++ 3 ++ 2 +++ 
2x106, vaccinated 0 - 0 - 0 + 
 
*Histopathology: severity is based on the amount of architectural change, cellular 
infiltration, and the presence or absence of necrosis: 0, none; 1, mild; 2, mild to 
moderate; 3, moderate; 4, moderate to severe; 5, severe.  
#Immunohistochemistry: -, no organisms present in the tissue section; +, the presence of 
the organism is rare and focal; ++, few organisms are multifocally present; +++, many 
organisms are diffusely present; ++++, abundance of organisms are diffusely present. 
Scores are the average of sections evaluated for 3 guinea pigs per group at 28 days p.i. 
The evaluation of tissue sections was performed in a blinded fashion. 
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TABLE 3.1. Isolates tested for virulence in aerosol-challenged guinea pigs 
Genomic   Original Source   
Group Isolate Sample Year Location Disease 
I Nine Mile RSA493 Tick 1935 Montana, US n/a (acute, flu-like in humans) 
 African RSA334 Human Blood 1949 Central Africa Acute, Congolese Red Fever 
  Ohio 314 RSA270 Cow's Milk 1956 Ohio, US Persistent 
IV MSU Goat Q177 Goat Cotyledon 1980 Montana, US Abortion 
  P Q173 Human Heart Valve 1979 California, US Endocarditis 
V G Q212 Human Heart Valve 1981 Nova Scotia, Canada Endocarditis 
  S Q217 Human Liver Biopsy 1981 Montana, US Hepatitis 
VI Dugway 5J108-111 Rodents 1958 Utah, US n/a 
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TABLE 3.2. Comparison of OD, particle count, and real-time PCR quantification of C. 
burnetii inoculum 
Group  Isolate  OD  Particle Count  Real-time PCR 
I  RSA493 2x106  1.7x106  1.1x106 
I  RSA334 2x106  2.6x106  3.6x106 
I  RSA270 2x106  2.8x106  4.2x106 
IV  Q177  2x106  8.9x104  5.5x104 
IV  Q173  2x106  1.0x106  9.8x105 
V  Q212  2x106  4.1x105  6.3x105 
V  Q217  2x106  3.4x104  2.6x104 
VI  5J108-111 2x106  6.5x105  1.3x105 
 
High dose delivered to infected guinea pigs as determined by optical density, viable 
particle count, and real-time PCR amplification of com-1. 
  
115
 
TABLE 3.3. Response to infection with different C. burnetii isolates 
  Fever/ Death/ Seroconversion/ 
Strain Dose Total Total Total 
RSA493 2x10
2 3/3 0/3 3/3 
 2x10
4 3/3 0/3 3/3 
 2x10
6 3/3 2/3 1/3* 
RSA334 2x10
2 3/3 0/3 3/3 
 2x10
4 3/3 0/3 3/3 
 2x10
6 3/3 3/3 0/3* 
RSA270 2x10
2 3/3 0/3 3/3 
 2x10
4 3/3 0/3 3/3 
  2x10
6 3/3 3/3 0/3* 
Q177 2x10
2 0/3 0/3 3/3 
 2x10
4 0/3 0/3 3/3 
 2x10
6 0/3 0/3 3/3 
Q173 2x10
2 0/3 0/3 3/3 
 2x10
4 0/3 0/3 3/3 
  2x10
6 1/3 0/3 3/3 
Q212 2x10
2 0/3 0/3 3/3 
 2x10
4 2/3 0/3 3/3 
 2x10
6 3/3 0/3 3/3 
Q217 2x10
2 3/3 0/3 3/3 
 2x10
4 3/3 0/3 3/3 
  2x10
6 3/3 0/3 3/3 
5J108-111 2x10
2 0/3 0/3 0/3 
 2x10
4 0/3 0/3 3/3 
  2x10
6 0/3 0/3 3/3 
PBS 
Control N/A 0/4 0/4 0/4 
  *Numbers may be skewed due to death. 
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TABLE 3.4. Severity* of histopathologic changes in guinea pigs infected with high dose 
C. burnetii 28 days post infection 
 Lung Liver Spleen 
RSA493 3 2 2 
Q177 1 2 1.33 
Q173 1 3 2 
Q212 2 1.33 1.33 
Q217 2.67 2 1 
5J108-111 0 0 0 
 
*Severity is based on the amount of architectural change, cellular infiltration, and the 
presence or absence of necrosis: 0, none; 1, mild; 2, mild to moderate; 3, moderate; 4, 
moderate to severe; 5, severe. Scores are the average of sections evaluated in a blinded 
fashion for 3 guinea pigs per group, with the exception of RSA493. 
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Table 4.1. Real-time PCR primers for guinea pig genes 
mRNA    Primer      
IFN-γ   Forward 5’ ATTTCGGTCAATGACGAGCAT 3’ 
   Reverse 5’ GTTTCCTCTGGTTCGGTGACA 3’ 
TNF-α   Forward 5’ CCTACCTGCTTCTCACCCATACC 3’ 
   Reverse 5’ TTGATGGCAGAGAGAAGGTTGA 3’ 
TGF-β   Forward 5’ CATCGATATGGAGCTGGTGAAG 3’ 
   Reverse 5’ GCCGTAATTTGGACAGGATCTG 3’ 
RANTES  Forward 5’ CTGGCCCACTGCTTAGCAAT 3’ 
   Reverse 5’ CCTTGCTTCTTTGCCTTGAAA 3’ 
IL-1β   Forward 5’ GCCCAGGCAACAGCTCTC 3’ 
   Reverse 5’ GGAGTCTCTACCAGCTCAACTTGG 3’ 
IL-8   Forward 5’ GGCAGCCTTCCTGCTCTCT 3’ 
   Reverse 5’ CAGCTCCGAGACCAACTTTGT 3’ 
IL-10   Forward 5’ CCTTACTGGCCGGGGTCA 3’ 
   Reverse 5’ GCTGATCCTGTGTTTGGAAGAAAG 3’ 
IL-12p40  Forward 5’ CCACAGTTTCATGCCACAAGA 3’ 
   Reverse 5’ CCATTCGCTCCACGATGAG 3’ 
HPRT   Forward 5’ AGGTGTTTATCCCTCATGGACTAATT 3’ 
Reverse 5’ CCTCCCATCTCCTTCATCACAT 3’
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